,Gene_set,Term,Overlap,P-value,Adjusted P-value,Odds Ratio,Genes,group,ordered_group,sample
0,gs_ind_0,Bacterial invasion of epithelial cells,1/2,0.025103712371024357,0.1124893853701103,56.76,FN1_ITGA5,1,1,A1
1,gs_ind_0,ECM-receptor interaction,2/101,0.38694945903699385,0.38694945903699385,2.257799671592775,COL1A1_ITGAV;FN1_ITGA5,1,1,A1
2,gs_ind_0,Fibronectin matrix formation,1/2,0.025103712371024357,0.1124893853701103,56.76,FN1_ITGA5,1,1,A1
3,gs_ind_0,Focal adhesion,3/110,0.09727598398295166,0.19509067733508334,8.14027149321267,COL1A1_ITGAV;COL1A1_ITGA5;FN1_ITGA5,1,1,A1
4,gs_ind_0,Human papillomavirus infection,3/114,0.10838370963060186,0.19509067733508334,7.611353711790393,COL1A1_ITGAV;COL1A1_ITGA5;FN1_ITGA5,1,1,A1
5,gs_ind_0,PI3K-Akt signaling pathway,3/127,0.15026124159168067,0.225391862387521,6.12156862745098,COL1A1_ITGAV;COL1A1_ITGA5;FN1_ITGA5,1,1,A1
6,gs_ind_0,Proteoglycans in cancer,1/20,0.2324040536617994,0.26145456036952436,6.3951219512195125,FN1_ITGA5,1,1,A1
7,gs_ind_0,Regulation of actin cytoskeleton,1/18,0.21098368547161409,0.26145456036952436,7.151351351351352,FN1_ITGA5,1,1,A1
8,gs_ind_0,Yersinia infection,1/3,0.03749646179003677,0.1124893853701103,40.371428571428574,FN1_ITGA5,1,1,A1
0,gs_ind_0,Focal adhesion,1/110,0.7118037088253023,0.7835336666312095,1.16289592760181,FN1_ITGA6,2,2,A1
1,gs_ind_0,Human papillomavirus infection,1/114,0.7296032336985427,0.7835336666312095,1.0873362445414847,FN1_ITGA6,2,2,A1
2,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.008403361344537815,0.037815126050420166,158.33333333333334,ADAM10_NOTCH2,2,2,A1
3,gs_ind_0,PI3K-Akt signaling pathway,1/127,0.7835336666312095,0.7835336666312095,0.8745098039215686,FN1_ITGA6,2,2,A1
4,gs_ind_0,Pathways in cancer,1/76,0.537602382725242,0.7835336666312095,2.1241830065359477,FN1_ITGA6,2,2,A1
5,gs_ind_0,Regulation of actin cytoskeleton,1/18,0.14583554940963728,0.3281299861716839,11.91891891891892,FN1_ITGA6,2,2,A1
6,gs_ind_0,Signaling by NOTCH,1/3,0.025103712371024357,0.07531113711307308,67.28571428571429,ADAM10_NOTCH2,2,2,A1
7,gs_ind_0,Signaling by NOTCH2,1/1,0.008403361344537815,0.037815126050420166,158.33333333333334,ADAM10_NOTCH2,2,2,A1
8,gs_ind_0,Small cell lung cancer,1/41,0.31546289401836675,0.5678332092330601,4.759036144578313,FN1_ITGA6,2,2,A1
0,gs_ind_0,Apelin signaling pathway,1/4,0.58780620164822,0.7455103045294497,1.6810035842293907,GNAI2_ADCY9,3,3,A1
1,gs_ind_0,Axon guidance,5/14,0.1179118621456084,0.5109514026309697,2.0036511156186614,EFNB1_EPHB4;SEMA4C_PLXNB2;SEMA4D_PLXNB2;EFNB1_EPHB3;EFNB1_EPHB6,3,3,A1
2,gs_ind_0,Bacterial invasion of epithelial cells,1/2,0.35662872744034313,0.6394722009275118,3.0516129032258066,FN1_ITGB1,3,3,A1
3,gs_ind_0,Basal cell carcinoma,3/5,0.054068078141427715,0.46859001055904015,3.3391215526046985,WNT7B_FZD4;WNT7B_FZD1;WNT3A_FZD2,3,3,A1
4,gs_ind_0,Breast cancer,6/21,0.21298862438396512,0.6394722009275118,1.5844774446623704,WNT7B_LRP5;WNT7B_FZD4;WNT7B_FZD1;JAG2_NOTCH3;JAG2_NOTCH1;WNT3A_FZD2,3,3,A1
5,gs_ind_0,Chemokine signaling pathway,1/14,0.9583413277984234,0.9583413277984234,0.4994438264738598,GNAI2_ADCY9,3,3,A1
6,gs_ind_0,Cholinergic synapse,1/2,0.35662872744034313,0.6394722009275118,3.0516129032258066,GNAI2_ADCY9,3,3,A1
7,gs_ind_0,Circadian entrainment,1/4,0.58780620164822,0.7455103045294497,1.6810035842293907,GNAI2_ADCY9,3,3,A1
8,gs_ind_0,Cushing syndrome,4/9,0.07841510883037947,0.5096982073974665,2.499092558983666,WNT3A_FZD2;WNT7B_FZD4;WNT7B_FZD1;GNAI2_ADCY9,3,3,A1
9,gs_ind_0,ECM-receptor interaction,30/101,0.0008572218129518902,0.044575534273498287,2.361013370865588,LAMA5_ITGB4;COL6A2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;TNC_SDC4;FN1_ITGB6;LAMA5_ITGB1;LAMA2_ITGB4;LAMC2_ITGA2;COL6A1_ITGB1;TNC_SDC1;FN1_ITGB1;THBS1_ITGA3;FN1_ITGA3;COMP_ITGB1;LAMB2_ITGA3;TNC_ITGB6;LAMC2_ITGB1;TNC_ITGAV;LAMB3_ITGB1;LAMB2_ITGB4;COL1A2_ITGB1;COL1A1_ITGB1;LAMC2_ITGA3;LAMB1_ITGB4;LAMB3_ITGB4;LAMB3_ITGA3;LAMA5_ITGA3;THBS1_ITGB1;LAMC2_ITGB4,3,3,A1
10,gs_ind_0,Endocrine resistance,2/17,0.8860158516539389,0.9402617201225475,0.695447409733124,JAG2_NOTCH1;JAG2_NOTCH3,3,3,A1
11,gs_ind_0,Fibronectin matrix formation,1/2,0.35662872744034313,0.6394722009275118,3.0516129032258066,FN1_ITGB1,3,3,A1
12,gs_ind_0,Focal adhesion,28/110,0.029649678357637994,0.46859001055904015,1.6996171249564915,LAMA5_ITGB4;COL6A2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;FN1_ITGB6;LAMA5_ITGB1;LAMA2_ITGB4;LAMC2_ITGA2;COL6A1_ITGB1;FN1_ITGB1;THBS1_ITGA3;FN1_ITGA3;COMP_ITGB1;LAMB2_ITGA3;TNC_ITGB6;LAMC2_ITGB1;TNC_ITGAV;LAMB3_ITGB1;LAMB2_ITGB4;COL1A2_ITGB1;COL1A1_ITGB1;LAMC2_ITGA3;LAMB1_ITGB4;LAMB3_ITGB4;LAMB3_ITGA3;LAMA5_ITGA3;THBS1_ITGB1;LAMC2_ITGB4,3,3,A1
13,gs_ind_0,GABAergic synapse,1/2,0.35662872744034313,0.6394722009275118,3.0516129032258066,GNAI2_ADCY9,3,3,A1
14,gs_ind_0,Gap junction,1/6,0.7370433092279884,0.8710511836330772,1.1538461538461537,GNAI2_ADCY9,3,3,A1
15,gs_ind_0,Gastric acid secretion,1/4,0.58780620164822,0.7455103045294497,1.6810035842293907,GNAI2_ADCY9,3,3,A1
16,gs_ind_0,Gastric cancer,4/11,0.15074261558804097,0.5599011436127237,2.0464767616191906,WNT3A_FZD2;WNT7B_FZD4;WNT7B_FZD1;WNT7B_LRP5,3,3,A1
17,gs_ind_0,Glutamatergic synapse,1/4,0.58780620164822,0.7455103045294497,1.6810035842293907,GNAI2_ADCY9,3,3,A1
18,gs_ind_0,"Growth hormone synthesis, secretion and action",1/4,0.58780620164822,0.7455103045294497,1.6810035842293907,GNAI2_ADCY9,3,3,A1
19,gs_ind_0,Hepatocellular carcinoma,4/13,0.2407429312386332,0.6394722009275118,1.7279693486590038,WNT7B_LRP5;WNT7B_FZD4;WNT7B_FZD1;WNT3A_FZD2,3,3,A1
20,gs_ind_0,Hippo signaling pathway,3/10,0.31311983357667067,0.6394722009275118,1.7116104868913857,WNT7B_FZD4;WNT7B_FZD1;WNT3A_FZD2,3,3,A1
21,gs_ind_0,Human cytomegalovirus infection,1/7,0.7903147077895597,0.8933992348925458,0.9956989247311828,GNAI2_ADCY9,3,3,A1
22,gs_ind_0,Human papillomavirus infection,31/114,0.004486558675756602,0.11665052556967163,2.075823739579198,LAMA5_ITGB4;COL6A2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;WNT7B_FZD1;LAMA5_ITGB1;FN1_ITGB6;LAMA2_ITGB4;LAMC2_ITGA2;COL6A1_ITGB1;FN1_ITGB1;THBS1_ITGA3;FN1_ITGA3;COMP_ITGB1;LAMB2_ITGA3;TNC_ITGB6;LAMC2_ITGB1;TNC_ITGAV;LAMB3_ITGB1;LAMB2_ITGB4;COL1A2_ITGB1;COL1A1_ITGB1;WNT3A_FZD2;LAMC2_ITGA3;WNT7B_FZD4;LAMB1_ITGB4;LAMB3_ITGB4;LAMB3_ITGA3;LAMA5_ITGA3;THBS1_ITGB1;LAMC2_ITGB4,3,3,A1
23,gs_ind_0,MAPK signaling pathway,3/26,0.923302414617571,0.9414063835316411,0.6306974772100912,AREG_ERBB3;FGF6_FGFR4;FGF6_FGFR3,3,3,A1
24,gs_ind_0,Melanogenesis,3/8,0.19464361478289874,0.6394722009275118,2.132848645076008,WNT7B_FZD4;WNT7B_FZD1;WNT3A_FZD2,3,3,A1
25,gs_ind_0,Morphine addiction,1/4,0.58780620164822,0.7455103045294497,1.6810035842293907,GNAI2_ADCY9,3,3,A1
26,gs_ind_0,Notch signaling pathway,2/16,0.8630147569438228,0.9402617201225475,0.7409257409257409,JAG2_NOTCH1;JAG2_NOTCH3,3,3,A1
27,gs_ind_0,Oxytocin signaling pathway,1/4,0.58780620164822,0.7455103045294497,1.6810035842293907,GNAI2_ADCY9,3,3,A1
28,gs_ind_0,PI3K-Akt signaling pathway,31/127,0.03766856651470081,0.46859001055904015,1.66951871657754,LAMA5_ITGB4;FGF6_FGFR4;FGF6_FGFR3;COL6A2_ITGB1;LAMB3_ITGA2;TNC_ITGB1;FN1_ITGB6;LAMA5_ITGB1;AREG_ERBB3;LAMA2_ITGB4;LAMC2_ITGA2;COL6A1_ITGB1;FN1_ITGB1;THBS1_ITGA3;FN1_ITGA3;COMP_ITGB1;LAMB2_ITGA3;TNC_ITGB6;LAMC2_ITGB1;TNC_ITGAV;LAMB3_ITGB1;LAMB2_ITGB4;COL1A2_ITGB1;COL1A1_ITGB1;LAMC2_ITGA3;LAMB1_ITGB4;LAMB3_ITGB4;LAMB3_ITGA3;LAMA5_ITGA3;THBS1_ITGB1;LAMC2_ITGB4,3,3,A1
29,gs_ind_0,"Parathyroid hormone synthesis, secretion and action",1/4,0.58780620164822,0.7455103045294497,1.6810035842293907,GNAI2_ADCY9,3,3,A1
30,gs_ind_0,Pathways in cancer,19/76,0.11228009716210106,0.5109514026309697,1.4533883728930168,FGF6_FGFR4;FGF6_FGFR3;LAMB3_ITGA2;WNT7B_FZD1;LAMA5_ITGB1;LAMC2_ITGA2;FN1_ITGB1;FN1_ITGA3;LAMB2_ITGA3;LAMC2_ITGB1;LAMB3_ITGB1;JAG2_NOTCH3;JAG2_NOTCH1;WNT3A_FZD2;LAMC2_ITGA3;WNT7B_FZD4;LAMB3_ITGA3;LAMA5_ITGA3;WNT7B_LRP5,3,3,A1
31,gs_ind_0,Platelet activation,4/10,0.11191328085162956,0.5109514026309697,2.251231527093596,COL1A2_ITGB1;COL3A1_ITGB1;COL1A1_ITGB1;GNAI2_ADCY9,3,3,A1
32,gs_ind_0,Progesterone-mediated oocyte maturation,1/3,0.4847577520602748,0.7455103045294497,2.1705069124423964,GNAI2_ADCY9,3,3,A1
33,gs_ind_0,Proteoglycans in cancer,7/20,0.07293202162962222,0.5096982073974665,1.9738030713640469,HSPG2_ITGB1;WNT7B_FZD4;WNT7B_FZD1;FN1_ITGB1;COL1A2_ITGB1;COL1A1_ITGB1;WNT3A_FZD2,3,3,A1
34,gs_ind_0,Rap1 signaling pathway,2/17,0.8860158516539389,0.9402617201225475,0.695447409733124,FGF6_FGFR4;FGF6_FGFR3,3,3,A1
35,gs_ind_0,Ras signaling pathway,2/18,0.9054783164086526,0.9414063835316411,0.6548856548856549,FGF6_FGFR4;FGF6_FGFR3,3,3,A1
36,gs_ind_0,Regulation of actin cytoskeleton,5/18,0.26879481994127935,0.6394722009275118,1.5424483306836247,FGF6_FGFR4;FGF6_FGFR3;FN1_ITGB6;FN1_ITGB1;FN1_ITGA3,3,3,A1
37,gs_ind_0,Regulation of lipolysis in adipocytes,1/4,0.58780620164822,0.7455103045294497,1.6810035842293907,GNAI2_ADCY9,3,3,A1
38,gs_ind_0,Relaxin signaling pathway,1/6,0.7370433092279884,0.8710511836330772,1.1538461538461537,GNAI2_ADCY9,3,3,A1
39,gs_ind_0,Retrograde endocannabinoid signaling,1/2,0.35662872744034313,0.6394722009275118,3.0516129032258066,GNAI2_ADCY9,3,3,A1
40,gs_ind_0,Signaling Pathways,1/2,0.35662872744034313,0.6394722009275118,3.0516129032258066,FGF6_FGFR3,3,3,A1
41,gs_ind_0,Signaling by FGFR,1/2,0.35662872744034313,0.6394722009275118,3.0516129032258066,FGF6_FGFR3,3,3,A1
42,gs_ind_0,Signaling by Receptor Tyrosine Kinases,1/2,0.35662872744034313,0.6394722009275118,3.0516129032258066,FGF6_FGFR3,3,3,A1
43,gs_ind_0,Signaling pathways regulating pluripotency of stem cells,3/9,0.2527578677591583,0.6394722009275118,1.9000591366055588,WNT7B_FZD4;WNT7B_FZD1;WNT3A_FZD2,3,3,A1
44,gs_ind_0,Small cell lung cancer,11/41,0.15014482816447064,0.5599011436127237,1.4994223469219343,LAMB2_ITGA3;LAMC2_ITGA2;LAMC2_ITGB1;LAMC2_ITGA3;LAMB3_ITGA2;LAMA5_ITGB1;LAMB3_ITGA3;LAMB3_ITGB1;FN1_ITGB1;LAMA5_ITGA3;FN1_ITGA3,3,3,A1
45,gs_ind_0,TCF dependent signaling in response to WNT,1/4,0.58780620164822,0.7455103045294497,1.6810035842293907,WNT3A_FZD2,3,3,A1
46,gs_ind_0,Th1 and Th2 cell differentiation,1/7,0.7903147077895597,0.8933992348925458,0.9956989247311828,JAG2_NOTCH1,3,3,A1
47,gs_ind_0,Toxoplasmosis,3/9,0.2527578677591583,0.6394722009275118,1.9000591366055588,LAMA5_ITGB1;LAMB3_ITGB1;LAMC2_ITGB1,3,3,A1
48,gs_ind_0,Wnt signaling pathway,4/10,0.11191328085162956,0.5109514026309697,2.251231527093596,WNT3A_FZD2;WNT7B_FZD4;WNT7B_FZD1;WNT7B_LRP5,3,3,A1
49,gs_ind_0,Yersinia infection,1/3,0.4847577520602748,0.7455103045294497,2.1705069124423964,FN1_ITGB1,3,3,A1
50,gs_ind_0,cAMP signaling pathway,1/5,0.6705972637103295,0.8302632788794555,1.3695014662756597,GNAI2_ADCY9,3,3,A1
51,gs_ind_0,mTOR signaling pathway,4/8,0.05092019344376201,0.46859001055904015,2.8052738336713996,WNT7B_LRP5;WNT7B_FZD4;WNT7B_FZD1;WNT3A_FZD2,3,3,A1
0,gs_ind_0,Antigen processing and presentation,2/2,0.00436442989634479,0.04800872885979268,16.103448275862068,HLA-B_KLRD1;HLA-E_KLRD1,1,1,B1
1,gs_ind_0,Axon guidance,2/22,0.45466639560095323,0.6866601198918979,1.6360153256704981,EFNB3_EPHB3;SEMA4G_PLXNB2,1,1,B1
2,gs_ind_0,Cytokine-cytokine receptor interaction,2/51,0.899811456791072,0.9472000611112562,0.6176765985939069,LTB_LTBR;IL34_CSF1R,1,1,B1
3,gs_ind_0,ECM-receptor interaction,5/61,0.4035801089138361,0.6866601198918979,1.3570166136443973,COL6A2_ITGA1;LAMB1_ITGB4;LAMB2_ITGB4;LAMB3_ITGB4;LAMB3_ITGA3,1,1,B1
4,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/8,0.4361754003192215,0.6866601198918979,2.5901328273244784,GAS6_AXL,1,1,B1
5,gs_ind_0,Epstein-Barr virus infection,1/1,0.06808510638297872,0.37446808510638296,15.129032258064516,CALR_HLA-F,1,1,B1
6,gs_ind_0,Focal adhesion,5/67,0.4993891781031985,0.6866601198918979,1.1938808373590983,COL6A2_ITGA1;LAMB1_ITGB4;LAMB2_ITGB4;LAMB3_ITGB4;LAMB3_ITGA3,1,1,B1
7,gs_ind_0,Graft-versus-host disease,2/2,0.00436442989634479,0.04800872885979268,16.103448275862068,HLA-B_KLRD1;HLA-E_KLRD1,1,1,B1
8,gs_ind_0,Herpes simplex virus 1 infection,1/4,0.24718811333921276,0.6042376103847422,4.978494623655914,CALR_HLA-F,1,1,B1
9,gs_ind_0,Human cytomegalovirus infection,1/9,0.4759163412658845,0.6866601198918979,2.307300509337861,CALR_HLA-F,1,1,B1
10,gs_ind_0,Human immunodeficiency virus 1 infection,1/3,0.19142426988285818,0.5264167421778599,6.428571428571429,CALR_HLA-F,1,1,B1
11,gs_ind_0,Human papillomavirus infection,5/72,0.5767963454991352,0.7464423294694691,1.0785607196401799,COL6A2_ITGA1;LAMB1_ITGB4;LAMB2_ITGB4;LAMB3_ITGB4;LAMB3_ITGA3,1,1,B1
12,gs_ind_0,Legionellosis,1/3,0.19142426988285818,0.5264167421778599,6.428571428571429,C3_ITGB2,1,1,B1
13,gs_ind_0,Leishmaniasis,1/2,0.13180578286961264,0.5264167421778599,9.038709677419355,C3_ITGB2,1,1,B1
14,gs_ind_0,NF-kappa B signaling pathway,1/5,0.2993309279997002,0.6585280415993404,4.055718475073314,LTB_LTBR,1,1,B1
15,gs_ind_0,Natural killer cell mediated cytotoxicity,1/3,0.19142426988285818,0.5264167421778599,6.428571428571429,HLA-E_KLRD1,1,1,B1
16,gs_ind_0,PI3K-Akt signaling pathway,5/84,0.7399949143952395,0.9044382287052926,0.8574736300488809,COL6A2_ITGA1;LAMB1_ITGB4;LAMB2_ITGB4;LAMB3_ITGB4;LAMB3_ITGA3,1,1,B1
17,gs_ind_0,Pathways in cancer,1/57,0.9901196265086215,0.9901196265086215,0.30042075736325385,LAMB3_ITGA3,1,1,B1
18,gs_ind_0,Proteoglycans in cancer,1/8,0.4361754003192215,0.6866601198918979,2.5901328273244784,DCN_MET,1,1,B1
19,gs_ind_0,Small cell lung cancer,1/25,0.844860013087801,0.9472000611112562,0.7988614800759013,LAMB3_ITGA3,1,1,B1
20,gs_ind_0,Tuberculosis,2/6,0.05561994643437851,0.37446808510638296,6.087533156498674,C3_ITGB2;C3_ITGAX,1,1,B1
21,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,1/31,0.9041455128789264,0.9472000611112562,0.6282642089093702,IL34_CSF1R,1,1,B1
0,gs_ind_0,Adrenergic signaling in cardiomyocytes,1/2,0.13180578286961264,0.2987397750076862,9.038709677419355,GNAS_ADCY7,2,2,B1
1,gs_ind_0,Aldosterone synthesis and secretion,1/2,0.13180578286961264,0.2987397750076862,9.038709677419355,GNAS_ADCY7,2,2,B1
2,gs_ind_0,Bacterial invasion of epithelial cells,1/1,0.06808510638297872,0.2987397750076862,15.129032258064516,FN1_ITGA5,2,2,B1
3,gs_ind_0,Bile secretion,1/2,0.13180578286961264,0.2987397750076862,9.038709677419355,GNAS_ADCY7,2,2,B1
4,gs_ind_0,Calcium signaling pathway,1/2,0.13180578286961264,0.2987397750076862,9.038709677419355,GNAS_ADCY7,2,2,B1
5,gs_ind_0,Chemokine signaling pathway,6/35,0.018681037303973684,0.2987397750076862,3.4963112005365526,CXCL11_CXCR3;CXCL10_CXCR3;CCL5_CXCR3;CXCL9_CXCR3;CCL19_CXCR3;CXCL13_CXCR3,2,2,B1
6,gs_ind_0,Circadian entrainment,1/4,0.24718811333921276,0.3187425672005638,4.978494623655914,GNAS_ADCY7,2,2,B1
7,gs_ind_0,Cortisol synthesis and secretion,1/2,0.13180578286961264,0.2987397750076862,9.038709677419355,GNAS_ADCY7,2,2,B1
8,gs_ind_0,Cushing syndrome,1/6,0.3480731243127645,0.396641467240127,3.4168734491315136,GNAS_ADCY7,2,2,B1
9,gs_ind_0,Cytokine-cytokine receptor interaction,4/51,0.4718977928583811,0.5182200160450742,1.2897087378640777,CXCL11_CXCR3;CXCL10_CXCR3;CXCL13_CXCR3;CXCL9_CXCR3,2,2,B1
10,gs_ind_0,Dilated cardiomyopathy (DCM),1/2,0.13180578286961264,0.2987397750076862,9.038709677419355,GNAS_ADCY7,2,2,B1
11,gs_ind_0,ECM-receptor interaction,7/61,0.08685300300979361,0.2987397750076862,2.2400513478819,FN1_ITGAV;TNC_ITGAV;FN1_ITGB7;FN1_CD44;COL4A1_ITGAV;FN1_ITGA5;FN1_ITGA3,2,2,B1
12,gs_ind_0,Endocrine resistance,1/13,0.6100974810355139,0.6360590759731953,1.5949820788530467,GNAS_ADCY7,2,2,B1
13,gs_ind_0,Estrogen signaling pathway,1/2,0.13180578286961264,0.2987397750076862,9.038709677419355,GNAS_ADCY7,2,2,B1
14,gs_ind_0,Fibronectin matrix formation,1/1,0.06808510638297872,0.2987397750076862,15.129032258064516,FN1_ITGA5,2,2,B1
15,gs_ind_0,Focal adhesion,7/67,0.13412806224834892,0.2987397750076862,1.9707602339181287,FN1_ITGAV;FN1_ITGA6;TNC_ITGAV;FN1_ITGB7;COL4A1_ITGAV;FN1_ITGA5;FN1_ITGA3,2,2,B1
16,gs_ind_0,Gap junction,1/6,0.3480731243127645,0.396641467240127,3.4168734491315136,GNAS_ADCY7,2,2,B1
17,gs_ind_0,Gastric acid secretion,1/4,0.24718811333921276,0.3187425672005638,4.978494623655914,GNAS_ADCY7,2,2,B1
18,gs_ind_0,Glutamatergic synapse,1/4,0.24718811333921276,0.3187425672005638,4.978494623655914,GNAS_ADCY7,2,2,B1
19,gs_ind_0,GnRH signaling pathway,1/2,0.13180578286961264,0.2987397750076862,9.038709677419355,GNAS_ADCY7,2,2,B1
20,gs_ind_0,"Growth hormone synthesis, secretion and action",1/4,0.24718811333921276,0.3187425672005638,4.978494623655914,GNAS_ADCY7,2,2,B1
21,gs_ind_0,Human cytomegalovirus infection,1/9,0.4759163412658845,0.5182200160450742,2.307300509337861,GNAS_ADCY7,2,2,B1
22,gs_ind_0,Human papillomavirus infection,7/72,0.18299224940761066,0.3187425672005638,1.780399274047187,FN1_ITGAV;FN1_ITGA6;TNC_ITGAV;FN1_ITGB7;COL4A1_ITGAV;FN1_ITGA5;FN1_ITGA3,2,2,B1
23,gs_ind_0,Inflammatory mediator regulation of TRP channels,1/3,0.19142426988285818,0.3187425672005638,6.428571428571429,GNAS_ADCY7,2,2,B1
24,gs_ind_0,Insulin secretion,1/2,0.13180578286961264,0.2987397750076862,9.038709677419355,GNAS_ADCY7,2,2,B1
25,gs_ind_0,MAPK signaling pathway,1/26,0.8566802025668258,0.8566802025668258,0.7650639074863055,EREG_ERBB3,2,2,B1
26,gs_ind_0,Melanogenesis,1/5,0.2993309279997002,0.3760824479996233,4.055718475073314,GNAS_ADCY7,2,2,B1
27,gs_ind_0,Morphine addiction,1/4,0.24718811333921276,0.3187425672005638,4.978494623655914,GNAS_ADCY7,2,2,B1
28,gs_ind_0,Ovarian steroidogenesis,1/3,0.19142426988285818,0.3187425672005638,6.428571428571429,GNAS_ADCY7,2,2,B1
29,gs_ind_0,Oxytocin signaling pathway,1/4,0.24718811333921276,0.3187425672005638,4.978494623655914,GNAS_ADCY7,2,2,B1
30,gs_ind_0,PI3K-Akt signaling pathway,8/84,0.16746857601091383,0.3187425672005638,1.7928994082840237,FN1_ITGAV;FN1_ITGA6;TNC_ITGAV;FN1_ITGB7;EREG_ERBB3;COL4A1_ITGAV;FN1_ITGA5;FN1_ITGA3,2,2,B1
31,gs_ind_0,Pancreatic secretion,1/2,0.13180578286961264,0.2987397750076862,9.038709677419355,GNAS_ADCY7,2,2,B1
32,gs_ind_0,"Parathyroid hormone synthesis, secretion and action",1/4,0.24718811333921276,0.3187425672005638,4.978494623655914,GNAS_ADCY7,2,2,B1
33,gs_ind_0,Pathways in cancer,4/57,0.5730356931852991,0.6104075862191229,1.1175652173913044,FN1_ITGAV;COL4A1_ITGAV;FN1_ITGA6;FN1_ITGA3,2,2,B1
34,gs_ind_0,Phospholipase D signaling pathway,1/4,0.24718811333921276,0.3187425672005638,4.978494623655914,GNAS_ADCY7,2,2,B1
35,gs_ind_0,Platelet activation,1/4,0.24718811333921276,0.3187425672005638,4.978494623655914,GNAS_ADCY7,2,2,B1
36,gs_ind_0,Proteoglycans in cancer,2/8,0.09575300051195902,0.2987397750076862,4.614604462474645,FN1_ITGAV;FN1_ITGA5,2,2,B1
37,gs_ind_0,Rap1 signaling pathway,1/18,0.7327078774207783,0.7479726248670445,1.1377506538796862,GNAS_ADCY7,2,2,B1
38,gs_ind_0,Regulation of actin cytoskeleton,5/18,0.003823537956094966,0.18735335984865334,5.622796709753231,FN1_ITGAV;FN1_ITGA6;FN1_ITGB7;FN1_ITGA5;FN1_ITGA3,2,2,B1
39,gs_ind_0,Regulation of lipolysis in adipocytes,1/4,0.24718811333921276,0.3187425672005638,4.978494623655914,GNAS_ADCY7,2,2,B1
40,gs_ind_0,Relaxin signaling pathway,1/6,0.3480731243127645,0.396641467240127,3.4168734491315136,GNAS_ADCY7,2,2,B1
41,gs_ind_0,Salivary secretion,1/2,0.13180578286961264,0.2987397750076862,9.038709677419355,GNAS_ADCY7,2,2,B1
42,gs_ind_0,Small cell lung cancer,4/25,0.07513338856538183,0.2987397750076862,2.971764705882353,FN1_ITGAV;COL4A1_ITGAV;FN1_ITGA6;FN1_ITGA3,2,2,B1
43,gs_ind_0,Thermogenesis,1/2,0.13180578286961264,0.2987397750076862,9.038709677419355,GNAS_ADCY7,2,2,B1
44,gs_ind_0,Thyroid hormone synthesis,1/2,0.13180578286961264,0.2987397750076862,9.038709677419355,GNAS_ADCY7,2,2,B1
45,gs_ind_0,Vascular smooth muscle contraction,1/3,0.19142426988285818,0.3187425672005638,6.428571428571429,GNAS_ADCY7,2,2,B1
46,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,4/31,0.14362425233572185,0.30598210280219,2.337142857142857,CXCL11_CXCR3;CXCL10_CXCR3;CXCL13_CXCR3;CXCL9_CXCR3,2,2,B1
47,gs_ind_0,Yersinia infection,1/2,0.13180578286961264,0.2987397750076862,9.038709677419355,FN1_ITGA5,2,2,B1
48,gs_ind_0,cAMP signaling pathway,1/6,0.3480731243127645,0.396641467240127,3.4168734491315136,GNAS_ADCY7,2,2,B1
0,gs_ind_0,Activated NOTCH1 Transmits Signal to the Nucleus,1/2,0.36068376068376073,0.48091168091168096,3.0129032258064514,ADAM10_NOTCH1,3,3,B1
1,gs_ind_0,Adrenergic signaling in cardiomyocytes,2/2,0.03931623931623932,0.20641025641025645,5.131868131868132,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
2,gs_ind_0,Aldosterone synthesis and secretion,2/2,0.03931623931623932,0.20641025641025645,5.131868131868132,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
3,gs_ind_0,Axon guidance,9/22,0.015161717283432985,0.20641025641025645,2.3414141414141416,SEMA3C_NRP1;EFNA1_EPHA2;EFNB2_EPHB4;EFNA4_EPHA1;SEMA4C_PLXNB2;EFNA1_EPHA1;EFNA4_EPHA2;SEMA3B_NRP1;SEMA3F_NRP1,3,3,B1
4,gs_ind_0,Bile secretion,2/2,0.03931623931623932,0.20641025641025645,5.131868131868132,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
5,gs_ind_0,Breast cancer,1/16,0.9753910841594331,0.9915836448346699,0.4291300097751711,WNT7B_LRP5,3,3,B1
6,gs_ind_0,Calcium signaling pathway,2/2,0.03931623931623932,0.20641025641025645,5.131868131868132,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
7,gs_ind_0,Chemokine signaling pathway,3/35,0.986957448314228,0.9915836448346699,0.44421585693938914,CXCL10_CXCR3;CXCL13_CXCR3;CXCL9_CXCR3,3,3,B1
8,gs_ind_0,Choline metabolism in cancer,1/2,0.36068376068376073,0.48091168091168096,3.0129032258064514,PDGFC_PDGFRB,3,3,B1
9,gs_ind_0,Circadian entrainment,2/4,0.17947162107292342,0.38181818181818183,2.826617826617827,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
10,gs_ind_0,Constitutive Signaling by NOTCH1 HD Domain Mutants,1/2,0.36068376068376073,0.48091168091168096,3.0129032258064514,ADAM10_NOTCH1,3,3,B1
11,gs_ind_0,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,1/2,0.36068376068376073,0.48091168091168096,3.0129032258064514,ADAM10_NOTCH1,3,3,B1
12,gs_ind_0,Constitutive Signaling by NOTCH1 PEST Domain Mutants,1/2,0.36068376068376073,0.48091168091168096,3.0129032258064514,ADAM10_NOTCH1,3,3,B1
13,gs_ind_0,Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1/2,0.36068376068376073,0.48091168091168096,3.0129032258064514,ADAM10_NOTCH1,3,3,B1
14,gs_ind_0,Constitutive Signaling by Overexpressed ERBB2,1/1,0.2,0.38181818181818183,5.043010752688172,HSP90AA1_ERBB2,3,3,B1
15,gs_ind_0,Cortisol synthesis and secretion,2/2,0.03931623931623932,0.20641025641025645,5.131868131868132,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
16,gs_ind_0,Cushing syndrome,2/6,0.34462863366222857,0.48091168091168096,1.9399830938292477,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
17,gs_ind_0,Cytokine-cytokine receptor interaction,5/51,0.9915836448346699,0.9915836448346699,0.46362078812107366,CXCL10_CXCR3;IL20_IL20RA;CXCL9_CXCR3;OSM_OSMR;CXCL13_CXCR3,3,3,B1
18,gs_ind_0,Dilated cardiomyopathy (DCM),2/2,0.03931623931623932,0.20641025641025645,5.131868131868132,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
19,gs_ind_0,ECM-receptor interaction,16/61,0.11115677416745397,0.38181818181818183,1.48625629113434,COL1A1_ITGAV;FN1_ITGAV;COL4A5_ITGAV;LAMA5_ITGA6;TNC_ITGAV;TNC_SDC1;FN1_ITGB7;COL1A2_ITGAV;COL1A2_CD44;COL1A1_CD44;TNC_SDC4;FN1_CD44;LAMA5_ITGA3;COL4A1_ITGAV;COL4A1_ITGA1;FN1_ITGA3,3,3,B1
20,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/8,0.8372708960066242,0.8902627248678029,0.8633776091081594,PDGFC_PDGFRB,3,3,B1
21,gs_ind_0,Endocrine and other factor-regulated calcium reabsorption,1/1,0.2,0.38181818181818183,5.043010752688172,GNAS_ADCY9,3,3,B1
22,gs_ind_0,Endocrine resistance,2/13,0.7745298392609635,0.8902627248678029,0.9055759055759056,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
23,gs_ind_0,Estrogen signaling pathway,2/2,0.03931623931623932,0.20641025641025645,5.131868131868132,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
24,gs_ind_0,Focal adhesion,18/67,0.07129855680247804,0.35229875125930327,1.565473948524796,COL1A1_ITGAV;PDGFC_PDGFRB;FN1_ITGAV;COL4A5_ITGAV;FN1_ITGA6;LAMA5_ITGA6;TNC_ITGAV;COL4A2_ITGB5;FN1_ITGB7;TLN1_ITGB5;COL1A2_ITGAV;FN1_ITGA9;LAMA5_ITGA3;THBS1_ITGA6;COL6A1_ITGA6;COL4A1_ITGAV;COL4A1_ITGA1;FN1_ITGA3,3,3,B1
25,gs_ind_0,Gap junction,3/6,0.09622174480839567,0.38181818181818183,2.777009507346586,GNAS_ADCY9;PDGFC_PDGFRB;GNAS_ADCY7,3,3,B1
26,gs_ind_0,Gastric acid secretion,2/4,0.17947162107292342,0.38181818181818183,2.826617826617827,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
27,gs_ind_0,Gastric cancer,1/8,0.8372708960066242,0.8902627248678029,0.8633776091081594,WNT7B_LRP5,3,3,B1
28,gs_ind_0,Glutamatergic synapse,2/4,0.17947162107292342,0.38181818181818183,2.826617826617827,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
29,gs_ind_0,GnRH signaling pathway,2/2,0.03931623931623932,0.20641025641025645,5.131868131868132,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
30,gs_ind_0,"Growth hormone synthesis, secretion and action",2/4,0.17947162107292342,0.38181818181818183,2.826617826617827,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
31,gs_ind_0,Hepatocellular carcinoma,1/8,0.8372708960066242,0.8902627248678029,0.8633776091081594,WNT7B_LRP5,3,3,B1
32,gs_ind_0,Human cytomegalovirus infection,2/9,0.5677284153832352,0.7013115719439964,1.3100057836899943,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
33,gs_ind_0,Human papillomavirus infection,16/72,0.34442489619761824,0.48091168091168096,1.18128078817734,COL1A1_ITGAV;FN1_ITGAV;COL4A5_ITGAV;FN1_ITGA6;LAMA5_ITGA6;TNC_ITGAV;COL4A2_ITGB5;FN1_ITGB7;COL1A2_ITGAV;FN1_ITGA9;LAMA5_ITGA3;THBS1_ITGA6;COL6A1_ITGA6;COL4A1_ITGAV;COL4A1_ITGA1;FN1_ITGA3,3,3,B1
34,gs_ind_0,Inflammatory mediator regulation of TRP channels,2/3,0.10276218774072851,0.38181818181818183,3.6499215070643642,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
35,gs_ind_0,Insulin secretion,2/2,0.03931623931623932,0.20641025641025645,5.131868131868132,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
36,gs_ind_0,JAK-STAT signaling pathway,2/9,0.5677284153832352,0.7013115719439964,1.3100057836899943,IL20_IL20RA;OSM_OSMR,3,3,B1
37,gs_ind_0,MAPK signaling pathway,4/26,0.8089601764056239,0.8902627248678029,0.8178269355888094,PDGFC_PDGFRB;AREG_ERBB3;EFNA1_EPHA2;EFNA4_EPHA2,3,3,B1
38,gs_ind_0,Melanogenesis,2/5,0.26182633737761746,0.4781176595591275,2.3026973026973026,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
39,gs_ind_0,Melanoma,1/5,0.6758378188006722,0.7995827715388234,1.3519061583577712,PDGFC_PDGFRB,3,3,B1
40,gs_ind_0,Morphine addiction,2/4,0.17947162107292342,0.38181818181818183,2.826617826617827,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
41,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.2,0.38181818181818183,5.043010752688172,ADAM10_NOTCH2,3,3,B1
42,gs_ind_0,Neuroactive ligand-receptor interaction,1/3,0.4896445471552767,0.6327714147852807,2.142857142857143,EDN2_EDNRA,3,3,B1
43,gs_ind_0,Ovarian steroidogenesis,2/3,0.10276218774072851,0.38181818181818183,3.6499215070643642,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
44,gs_ind_0,Oxytocin signaling pathway,2/4,0.17947162107292342,0.38181818181818183,2.826617826617827,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
45,gs_ind_0,PI3K-Akt signaling pathway,21/84,0.10481563543881448,0.38181818181818183,1.454616501060623,COL1A1_ITGAV;PDGFC_PDGFRB;FN1_ITGA6;LAMA5_ITGA6;AREG_ERBB3;OSM_OSMR;EFNA1_EPHA2;COL4A2_ITGB5;FN1_ITGB7;COL1A2_ITGAV;COL4A1_ITGAV;FN1_ITGA3;COL4A5_ITGAV;TNC_ITGAV;COL6A1_ITGA6;COL4A1_ITGA1;FN1_ITGAV;FN1_ITGA9;THBS1_ITGA6;LAMA5_ITGA3;EFNA4_EPHA2,3,3,B1
46,gs_ind_0,Pancreatic secretion,2/2,0.03931623931623932,0.20641025641025645,5.131868131868132,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
47,gs_ind_0,"Parathyroid hormone synthesis, secretion and action",2/4,0.17947162107292342,0.38181818181818183,2.826617826617827,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
48,gs_ind_0,Pathways in cancer,8/57,0.9349627439141307,0.9695909936887281,0.6680242157402312,FN1_ITGAV;COL4A5_ITGAV;FN1_ITGA6;LAMA5_ITGA6;LAMA5_ITGA3;COL4A1_ITGAV;FN1_ITGA3;WNT7B_LRP5,3,3,B1
49,gs_ind_0,Phospholipase D signaling pathway,3/4,0.026052754408533604,0.20641025641025645,4.046192259675406,GNAS_ADCY9;PDGFC_PDGFRB;GNAS_ADCY7,3,3,B1
50,gs_ind_0,Platelet activation,2/4,0.17947162107292342,0.38181818181818183,2.826617826617827,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
51,gs_ind_0,Prostate cancer,1/3,0.4896445471552767,0.6327714147852807,2.142857142857143,PDGFC_PDGFRB,3,3,B1
52,gs_ind_0,Proteoglycans in cancer,2/8,0.4992259064955233,0.6353784264488478,1.4705882352941178,FN1_ITGAV;FN1_SDC2,3,3,B1
53,gs_ind_0,Rap1 signaling pathway,5/18,0.27848389879923263,0.48091168091168096,1.521462639109698,PDGFC_PDGFRB;EFNA1_EPHA2;GNAS_ADCY9;GNAS_ADCY7;EFNA4_EPHA2,3,3,B1
54,gs_ind_0,Ras signaling pathway,3/16,0.6563237615369103,0.7875885138442923,1.0463057541709226,PDGFC_PDGFRB;EFNA1_EPHA2;EFNA4_EPHA2,3,3,B1
55,gs_ind_0,Regulation of actin cytoskeleton,6/18,0.1241621039408879,0.38181818181818183,1.841419732985998,PDGFC_PDGFRB;FN1_ITGAV;FN1_ITGA6;FN1_ITGB7;FN1_ITGA9;FN1_ITGA3,3,3,B1
56,gs_ind_0,Regulation of lipolysis in adipocytes,2/4,0.17947162107292342,0.38181818181818183,2.826617826617827,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
57,gs_ind_0,Relaxin signaling pathway,2/6,0.34462863366222857,0.48091168091168096,1.9399830938292477,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
58,gs_ind_0,Renin secretion,1/1,0.2,0.38181818181818183,5.043010752688172,EDN2_EDNRA,3,3,B1
59,gs_ind_0,Salivary secretion,2/2,0.03931623931623932,0.20641025641025645,5.131868131868132,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
60,gs_ind_0,Signaling by ERBB2,1/1,0.2,0.38181818181818183,5.043010752688172,HSP90AA1_ERBB2,3,3,B1
61,gs_ind_0,Signaling by ERBB2 ECD mutants,1/1,0.2,0.38181818181818183,5.043010752688172,HSP90AA1_ERBB2,3,3,B1
62,gs_ind_0,Signaling by ERBB2 KD Mutants,1/1,0.2,0.38181818181818183,5.043010752688172,HSP90AA1_ERBB2,3,3,B1
63,gs_ind_0,Signaling by ERBB2 in Cancer,1/1,0.2,0.38181818181818183,5.043010752688172,HSP90AA1_ERBB2,3,3,B1
64,gs_ind_0,Signaling by NOTCH,2/6,0.34462863366222857,0.48091168091168096,1.9399830938292477,ADAM10_NOTCH2;ADAM10_NOTCH1,3,3,B1
65,gs_ind_0,Signaling by NOTCH1,1/2,0.36068376068376073,0.48091168091168096,3.0129032258064514,ADAM10_NOTCH1,3,3,B1
66,gs_ind_0,Signaling by NOTCH1 HD Domain Mutants in Cancer,1/2,0.36068376068376073,0.48091168091168096,3.0129032258064514,ADAM10_NOTCH1,3,3,B1
67,gs_ind_0,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,1/2,0.36068376068376073,0.48091168091168096,3.0129032258064514,ADAM10_NOTCH1,3,3,B1
68,gs_ind_0,Signaling by NOTCH1 PEST Domain Mutants in Cancer,1/2,0.36068376068376073,0.48091168091168096,3.0129032258064514,ADAM10_NOTCH1,3,3,B1
69,gs_ind_0,Signaling by NOTCH1 in Cancer,1/2,0.36068376068376073,0.48091168091168096,3.0129032258064514,ADAM10_NOTCH1,3,3,B1
70,gs_ind_0,Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1/2,0.36068376068376073,0.48091168091168096,3.0129032258064514,ADAM10_NOTCH1,3,3,B1
71,gs_ind_0,Signaling by NOTCH2,1/1,0.2,0.38181818181818183,5.043010752688172,ADAM10_NOTCH2,3,3,B1
72,gs_ind_0,Small cell lung cancer,7/25,0.20918783944248362,0.39048396695930276,1.5286855482933914,FN1_ITGAV;COL4A5_ITGAV;FN1_ITGA6;LAMA5_ITGA6;LAMA5_ITGA3;COL4A1_ITGAV;FN1_ITGA3,3,3,B1
73,gs_ind_0,TGF-beta signaling pathway,1/7,0.7950152723177366,0.8902627248678029,0.9827956989247312,INHBB_ACVR1,3,3,B1
74,gs_ind_0,Thermogenesis,2/2,0.03931623931623932,0.20641025641025645,5.131868131868132,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
75,gs_ind_0,Thyroid hormone synthesis,2/2,0.03931623931623932,0.20641025641025645,5.131868131868132,GNAS_ADCY9;GNAS_ADCY7,3,3,B1
76,gs_ind_0,Toxoplasmosis,1/8,0.8372708960066242,0.8902627248678029,0.8633776091081594,LAMA5_ITGA6,3,3,B1
77,gs_ind_0,Vascular smooth muscle contraction,3/3,0.007593265103994718,0.20641025641025645,5.224719101123595,GNAS_ADCY9;EDN2_EDNRA;GNAS_ADCY7,3,3,B1
78,gs_ind_0,Vasopressin-regulated water reabsorption,1/1,0.2,0.38181818181818183,5.043010752688172,GNAS_ADCY9,3,3,B1
79,gs_ind_0,Vibrio cholerae infection,1/1,0.2,0.38181818181818183,5.043010752688172,GNAS_ADCY9,3,3,B1
80,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,4/31,0.9090225705426783,0.9544736990698123,0.6715927750410509,CXCL10_CXCR3;IL20_IL20RA;CXCL13_CXCR3;CXCL9_CXCR3,3,3,B1
81,gs_ind_0,Wnt signaling pathway,1/4,0.5930355225160613,0.7219562882804225,1.6594982078853047,WNT7B_LRP5,3,3,B1
82,gs_ind_0,cAMP signaling pathway,3/6,0.09622174480839567,0.38181818181818183,2.777009507346586,GNAS_ADCY9;EDN2_EDNRA;GNAS_ADCY7,3,3,B1
83,gs_ind_0,mTOR signaling pathway,1/6,0.7420796558283609,0.865759598466421,1.1389578163771712,WNT7B_LRP5,3,3,B1
0,gs_ind_0,Antigen processing and presentation,2/2,0.002000363702491362,0.016002909619930897,24.57894736842105,HLA-B_KLRD1;HLA-E_KLRD1,4,4,B1
1,gs_ind_0,Axon guidance,1/22,0.6691814281988366,0.8285232633128363,1.3555555555555556,SEMA4G_PLXNB2,4,4,B1
2,gs_ind_0,Chemokine signaling pathway,2/35,0.5078334818889404,0.8125335710223046,1.486286137879911,CCL19_CCR7;CXCL14_CXCR4,4,4,B1
3,gs_ind_0,Cytokine-cytokine receptor interaction,2/51,0.7321934772113471,0.8285232633128363,0.942769545222279,CCL19_CCR7;IL34_CSF1R,4,4,B1
4,gs_ind_0,ECM-receptor interaction,2/61,0.8285232633128363,0.8285232633128363,0.7466837826273,LAMA5_ITGB4;LAMB2_ITGB4,4,4,B1
5,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/8,0.3226028239971329,0.7108564756244992,3.823529411764706,GAS6_AXL,4,4,B1
6,gs_ind_0,Epstein-Barr virus infection,1/1,0.04680851063829788,0.249645390070922,22.333333333333332,CALR_HLA-F,4,4,B1
7,gs_ind_0,Focal adhesion,3/67,0.6527863372572256,0.8285232633128363,1.0278867102396514,LAMA5_ITGB4;COL1A1_ITGA5;LAMB2_ITGB4,4,4,B1
8,gs_ind_0,Graft-versus-host disease,2/2,0.002000363702491362,0.016002909619930897,24.57894736842105,HLA-B_KLRD1;HLA-E_KLRD1,4,4,B1
9,gs_ind_0,Herpes simplex virus 1 infection,1/4,0.17553826501962239,0.46810204005232636,7.349206349206349,CALR_HLA-F,4,4,B1
10,gs_ind_0,Human cytomegalovirus infection,1/9,0.3554282378122496,0.7108564756244992,3.406015037593985,CALR_HLA-F,4,4,B1
11,gs_ind_0,Human immunodeficiency virus 1 infection,1/3,0.13450170807489778,0.4304054658396729,9.489795918367347,CALR_HLA-F,4,4,B1
12,gs_ind_0,Human papillomavirus infection,3/72,0.7091851915253624,0.8285232633128363,0.9286004056795132,LAMA5_ITGB4;COL1A1_ITGA5;LAMB2_ITGB4,4,4,B1
13,gs_ind_0,Natural killer cell mediated cytotoxicity,1/3,0.13450170807489778,0.4304054658396729,9.489795918367347,HLA-E_KLRD1,4,4,B1
14,gs_ind_0,PI3K-Akt signaling pathway,3/84,0.8201955694308114,0.8285232633128363,0.7382526975287156,LAMA5_ITGB4;COL1A1_ITGA5;LAMB2_ITGB4,4,4,B1
15,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,2/31,0.43923874357220744,0.7808688774617021,1.70843776106934,CCL19_CCR7;IL34_CSF1R,4,4,B1
0,gs_ind_0,Antigen processing and presentation,2/2,0.0009322665943453793,0.015848532103871448,36.05263157894737,HLA-B_KLRD1;HLA-E_KLRD1,1,1,C1
1,gs_ind_0,Chemokine signaling pathway,1/32,0.6640459709556469,0.7525854337497332,1.3736263736263736,CCL5_CXCR3,1,1,C1
2,gs_ind_0,ECM-receptor interaction,4/116,0.5400679583245357,0.7525854337497332,1.176824034334764,COL6A2_ITGA1;FN1_ITGB8;COL1A2_ITGA1;COL1A1_ITGA1,1,1,C1
3,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/10,0.28064151933907333,0.4703327661107377,4.551020408163265,GAS6_AXL,1,1,C1
4,gs_ind_0,Epstein-Barr virus infection,1/1,0.03197674418604651,0.1359011627906977,32.714285714285715,CALR_HLA-F,1,1,C1
5,gs_ind_0,Focal adhesion,4/126,0.6213546737526172,0.7525854337497332,1.0363636363636364,COL6A2_ITGA1;FN1_ITGB8;COL1A2_ITGA1;COL1A1_ITGA1,1,1,C1
6,gs_ind_0,Graft-versus-host disease,2/3,0.002747733120175855,0.02335573152149477,25.67669172932331,HLA-B_KLRD1;HLA-E_KLRD1,1,1,C1
7,gs_ind_0,Herpes simplex virus 1 infection,1/2,0.06302122177774766,0.1759650470901189,19.571428571428573,CALR_HLA-F,1,1,C1
8,gs_ind_0,Human cytomegalovirus infection,1/11,0.30433296630694795,0.4703327661107377,4.142857142857143,CALR_HLA-F,1,1,C1
9,gs_ind_0,Human immunodeficiency virus 1 infection,1/3,0.09315796610653354,0.1759650470901189,13.938775510204081,CALR_HLA-F,1,1,C1
10,gs_ind_0,Human papillomavirus infection,4/142,0.7368762192224315,0.7829309829238335,0.8526315789473684,COL6A2_ITGA1;FN1_ITGB8;COL1A2_ITGA1;COL1A1_ITGA1,1,1,C1
11,gs_ind_0,Legionellosis,1/3,0.09315796610653354,0.1759650470901189,13.938775510204081,C3_ITGB2,1,1,C1
12,gs_ind_0,Leishmaniasis,1/2,0.06302122177774766,0.1759650470901189,19.571428571428573,C3_ITGB2,1,1,C1
13,gs_ind_0,Natural killer cell mediated cytotoxicity,1/3,0.09315796610653354,0.1759650470901189,13.938775510204081,HLA-E_KLRD1,1,1,C1
14,gs_ind_0,PI3K-Akt signaling pathway,4/150,0.7862417557552748,0.7862417557552748,0.7754152823920266,COL6A2_ITGA1;FN1_ITGB8;COL1A2_ITGA1;COL1A1_ITGA1,1,1,C1
15,gs_ind_0,Regulation of actin cytoskeleton,1/27,0.5987026265410559,0.7525854337497332,1.6493506493506493,FN1_ITGB8,1,1,C1
16,gs_ind_0,Tuberculosis,2/7,0.017919711232281026,0.10154503031625914,11.842105263157896,C3_ITGB2;C3_ITGAX,1,1,C1
0,gs_ind_0,Axon guidance,2/20,0.2589722758334071,0.45320148270846244,2.5531077891424077,SEMA4C_PLXNB2;EFNB2_EPHB3,2,2,C1
1,gs_ind_0,Cellular senescence,1/4,0.18424324963325445,0.4500621743031835,6.878787878787879,TGFB3_TGFBR1,2,2,C1
2,gs_ind_0,Chronic myeloid leukemia,1/4,0.18424324963325445,0.4500621743031835,6.878787878787879,TGFB3_TGFBR1,2,2,C1
3,gs_ind_0,Constitutive Signaling by Overexpressed ERBB2,1/1,0.04941860465116279,0.23062015503875968,20.818181818181817,HSP90AA1_ERBB2,2,2,C1
4,gs_ind_0,Cytokine-cytokine receptor interaction,1/71,0.9823422623655252,0.9823422623655252,0.3477431659249841,TGFB3_TGFBR1,2,2,C1
5,gs_ind_0,ECM-receptor interaction,7/116,0.33569293517343823,0.5529060108738983,1.4009809932556714,TNC_ITGB6;TNC_ITGAV;TNC_SDC1;TNC_SDC4;COL1A1_ITGA2;FN1_ITGB6;COL1A2_ITGA2,2,2,C1
6,gs_ind_0,Focal adhesion,8/126,0.2521168904502618,0.45320148270846244,1.5454545454545454,FN1_ITGA6;TNC_ITGB6;TNC_ITGA2;TNC_ITGAV;COL1A1_ITGA2;FN1_ITGA2;COL1A2_ITGA2;FN1_ITGB6,2,2,C1
7,gs_ind_0,FoxO signaling pathway,1/5,0.22503108715159176,0.4500621743031835,5.6115702479338845,TGFB3_TGFBR1,2,2,C1
8,gs_ind_0,Gastric cancer,1/24,0.7163812389691708,0.8700533430835139,1.189239332096475,TGFB3_TGFBR1,2,2,C1
9,gs_ind_0,Hepatitis B,1/4,0.18424324963325445,0.4500621743031835,6.878787878787879,TGFB3_TGFBR1,2,2,C1
10,gs_ind_0,Hepatocellular carcinoma,1/25,0.7314484856489334,0.8700533430835139,1.13903743315508,TGFB3_TGFBR1,2,2,C1
11,gs_ind_0,Hippo signaling pathway,1/29,0.7845088993360516,0.8786499672563778,0.9722650231124808,TGFB3_TGFBR1,2,2,C1
12,gs_ind_0,Human T-cell leukemia virus 1 infection,1/5,0.22503108715159176,0.4500621743031835,5.6115702479338845,TGFB3_TGFBR1,2,2,C1
13,gs_ind_0,Human papillomavirus infection,8/142,0.3991778150611408,0.5920528834295018,1.2714681440443214,FN1_ITGA6;TNC_ITGB6;TNC_ITGA2;TNC_ITGAV;COL1A1_ITGA2;FN1_ITGA2;COL1A2_ITGA2;FN1_ITGB6,2,2,C1
14,gs_ind_0,MAPK signaling pathway,1/36,0.8544226242401047,0.9201474414893436,0.7683686176836861,TGFB3_TGFBR1,2,2,C1
15,gs_ind_0,PI3K-Akt signaling pathway,8/150,0.4787036183611355,0.6701850657055897,1.1563210351460045,FN1_ITGA6;TNC_ITGB6;TNC_ITGA2;TNC_ITGAV;COL1A1_ITGA2;FN1_ITGA2;COL1A2_ITGA2;FN1_ITGB6,2,2,C1
16,gs_ind_0,Pancreatic cancer,1/5,0.22503108715159176,0.4500621743031835,5.6115702479338845,TGFB3_TGFBR1,2,2,C1
17,gs_ind_0,Pathways in cancer,3/100,0.915762449422347,0.9496795771787302,0.5872362326299537,TGFB3_TGFBR1;FN1_ITGA6;FN1_ITGA2,2,2,C1
18,gs_ind_0,Platelet activation,3/12,0.016783705012453944,0.09398874806974208,6.4206896551724135,COL1A2_ITGA2;COL1A1_ITGA2;COL3A1_ITGA2,2,2,C1
19,gs_ind_0,Proteoglycans in cancer,3/30,0.17653731462374087,0.4500621743031835,2.488976823063878,COL1A2_ITGA2;FN1_ITGA2;COL1A1_ITGA2,2,2,C1
20,gs_ind_0,Regulation of actin cytoskeleton,3/27,0.1396355183062067,0.4500621743031835,2.7868338557993733,FN1_ITGB6;FN1_ITGA6;FN1_ITGA2,2,2,C1
21,gs_ind_0,Signaling by ERBB2,2/2,0.0023052410332903926,0.01613668723303275,22.096774193548388,HSP90AA1_ERBB2;HSP90AA1_EGFR,2,2,C1
22,gs_ind_0,Signaling by ERBB2 ECD mutants,2/2,0.0023052410332903926,0.01613668723303275,22.096774193548388,HSP90AA1_ERBB2;HSP90AA1_EGFR,2,2,C1
23,gs_ind_0,Signaling by ERBB2 KD Mutants,2/2,0.0023052410332903926,0.01613668723303275,22.096774193548388,HSP90AA1_ERBB2;HSP90AA1_EGFR,2,2,C1
24,gs_ind_0,Signaling by ERBB2 in Cancer,2/2,0.0023052410332903926,0.01613668723303275,22.096774193548388,HSP90AA1_ERBB2;HSP90AA1_EGFR,2,2,C1
25,gs_ind_0,Small cell lung cancer,2/46,0.6913815074417169,0.8700533430835139,1.0353798126951093,FN1_ITGA6;FN1_ITGA2,2,2,C1
26,gs_ind_0,TCF dependent signaling in response to WNT,1/10,0.4017501708985905,0.5920528834295018,2.896103896103896,DKK1_LRP6,2,2,C1
27,gs_ind_0,Wnt signaling pathway,1/26,0.7457600083572976,0.8700533430835139,1.0926243567753002,DKK1_LRP6,2,2,C1
0,gs_ind_0,ECM-receptor interaction,4/123,0.11089859043245925,0.16018685284688558,3.149219201850781,COL1A1_ITGAV;COL1A1_CD44;FN1_ITGA4;FN1_ITGB7,1,1,D1
1,gs_ind_0,Epstein-Barr virus infection,1/1,0.01647058823529412,0.10705882352941176,65.3076923076923,CALR_HLA-F,1,1,D1
2,gs_ind_0,Focal adhesion,3/142,0.4311735146181647,0.5095686990941947,1.5473684210526315,COL1A1_ITGAV;FN1_ITGA4;FN1_ITGB7,1,1,D1
3,gs_ind_0,Herpes simplex virus 1 infection,1/5,0.08004961733584172,0.13967486357452913,17.643356643356643,CALR_HLA-F,1,1,D1
4,gs_ind_0,Human cytomegalovirus infection,1/10,0.15454270079192653,0.20090551102950446,9.131868131868131,CALR_HLA-F,1,1,D1
5,gs_ind_0,Human immunodeficiency virus 1 infection,1/4,0.06449490072074728,0.13967486357452913,21.615384615384617,CALR_HLA-F,1,1,D1
6,gs_ind_0,Human papillomavirus infection,3/163,0.5445755931250345,0.5707799369506307,1.2487257900101936,COL1A1_ITGAV;FN1_ITGA4;FN1_ITGB7,1,1,D1
7,gs_ind_0,Legionellosis,1/3,0.04871529663651891,0.12665977125494918,27.857142857142858,C3_ITGB2,1,1,D1
8,gs_ind_0,Leishmaniasis,1/2,0.03270810210876803,0.12665977125494918,39.09230769230769,C3_ITGB2,1,1,D1
9,gs_ind_0,PI3K-Akt signaling pathway,3/168,0.5707799369506307,0.5707799369506307,1.1885921529838444,COL1A1_ITGAV;FN1_ITGA4;FN1_ITGB7,1,1,D1
10,gs_ind_0,Regulation of actin cytoskeleton,2/31,0.08595376219971024,0.13967486357452913,5.692640692640692,FN1_ITGA4;FN1_ITGB7,1,1,D1
11,gs_ind_0,Tuberculosis,2/7,0.004704436830451853,0.06115767879587409,25.363636363636363,C3_ITGB2;C3_ITGAX,1,1,D1
12,gs_ind_0,Yersinia infection,1/3,0.04871529663651891,0.12665977125494918,27.857142857142858,FN1_ITGA4,1,1,D1
0,gs_ind_0,Axon guidance,1/39,0.5831156166447831,0.6608643655307541,1.7267311988086373,SEMA4C_PLXNB2,2,2,D1
1,gs_ind_0,Bacterial invasion of epithelial cells,1/2,0.04195338512763595,0.0792452830188679,29.894117647058824,FN1_ITGB1,2,2,D1
2,gs_ind_0,Constitutive Signaling by Overexpressed ERBB2,1/1,0.021176470588235293,0.0792452830188679,49.94117647058823,HSP90AA1_ERBB2,2,2,D1
3,gs_ind_0,ECM-receptor interaction,6/123,0.01997534668451052,0.0792452830188679,4.548872180451128,TNC_ITGB6;COMP_CD36;FN1_ITGB6;FN1_ITGB1;THBS2_CD36;THBS1_CD36,2,2,D1
4,gs_ind_0,Fibronectin matrix formation,1/2,0.04195338512763595,0.0792452830188679,29.894117647058824,FN1_ITGB1,2,2,D1
5,gs_ind_0,Focal adhesion,4/142,0.3506569715492017,0.49676404302803573,1.6277511961722488,FN1_ITGB6;FN1_ITGA6;TNC_ITGB6;FN1_ITGB1,2,2,D1
6,gs_ind_0,Human papillomavirus infection,4/163,0.4760596435445563,0.6144910434127904,1.3135946622185155,FN1_ITGB6;FN1_ITGA6;TNC_ITGB6;FN1_ITGB1,2,2,D1
7,gs_ind_0,PI3K-Akt signaling pathway,4/168,0.5060514475164156,0.6144910434127904,1.250337199892096,FN1_ITGB6;FN1_ITGA6;TNC_ITGB6;FN1_ITGB1,2,2,D1
8,gs_ind_0,Pathways in cancer,2/125,0.796296573865412,0.796296573865412,0.798140770252324,FN1_ITGA6;FN1_ITGB1,2,2,D1
9,gs_ind_0,Proteoglycans in cancer,1/47,0.655423290572078,0.6963872462328329,1.4061919504643963,FN1_ITGB1,2,2,D1
10,gs_ind_0,Regulation of actin cytoskeleton,3/31,0.021909931006569863,0.0792452830188679,6.743589743589744,FN1_ITGA6;FN1_ITGB6;FN1_ITGB1,2,2,D1
11,gs_ind_0,Signaling by ERBB2,1/2,0.04195338512763595,0.0792452830188679,29.894117647058824,HSP90AA1_ERBB2,2,2,D1
12,gs_ind_0,Signaling by ERBB2 ECD mutants,1/2,0.04195338512763595,0.0792452830188679,29.894117647058824,HSP90AA1_ERBB2,2,2,D1
13,gs_ind_0,Signaling by ERBB2 KD Mutants,1/2,0.04195338512763595,0.0792452830188679,29.894117647058824,HSP90AA1_ERBB2,2,2,D1
14,gs_ind_0,Signaling by ERBB2 in Cancer,1/2,0.04195338512763595,0.0792452830188679,29.894117647058824,HSP90AA1_ERBB2,2,2,D1
15,gs_ind_0,Small cell lung cancer,2/48,0.26982554430749867,0.41700311392977063,2.5945017182130585,FN1_ITGA6;FN1_ITGB1,2,2,D1
16,gs_ind_0,Yersinia infection,1/3,0.0623373556568352,0.10597350461661983,21.30252100840336,FN1_ITGB1,2,2,D1
0,gs_ind_0,Legionellosis,1/1,0.006756756756756758,0.010135135135135137,295.0,C3_ITGB2,1,1,F1
1,gs_ind_0,Leishmaniasis,1/1,0.006756756756756758,0.010135135135135137,295.0,C3_ITGB2,1,1,F1
2,gs_ind_0,Tuberculosis,1/3,0.020270270270270275,0.020270270270270275,124.71428571428571,C3_ITGB2,1,1,F1
0,gs_ind_0,Axon guidance,1/14,0.508800499679168,0.6105605996150015,2.140583554376658,EFNB2_EPHB4,2,2,F1
1,gs_ind_0,Constitutive Signaling by Overexpressed ERBB2,1/1,0.04729729729729731,0.10641891891891894,22.692307692307693,HSP90AA1_ERBB2,2,2,F1
2,gs_ind_0,ECM-receptor interaction,3/50,0.4399351754764344,0.5834907475687442,1.517051705170517,COL1A1_CD44;FN1_ITGB6;FN1_CD44,2,2,F1
3,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/6,0.2561213867307396,0.4191077237412102,5.059171597633136,TGFA_ERBB2,2,2,F1
4,gs_ind_0,Focal adhesion,1/50,0.9482268611583946,0.9645464419244083,0.4501142421934501,FN1_ITGB6,2,2,F1
5,gs_ind_0,Human papillomavirus infection,1/55,0.9645464419244083,0.9645464419244083,0.3887733887733888,FN1_ITGB6,2,2,F1
6,gs_ind_0,MAPK signaling pathway,1/12,0.45382613699791213,0.5834907475687442,2.52,TGFA_ERBB2,2,2,F1
7,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.04729729729729731,0.10641891891891894,22.692307692307693,ADAM10_NOTCH2,2,2,F1
8,gs_ind_0,Non-small cell lung cancer,1/1,0.04729729729729731,0.10641891891891894,22.692307692307693,TGFA_ERBB2,2,2,F1
9,gs_ind_0,PI3K-Akt signaling pathway,2/57,0.8275223350469347,0.9309626269278016,0.7233201581027668,TGFA_ERBB2;FN1_ITGB6,2,2,F1
10,gs_ind_0,Prostate cancer,1/3,0.13616649918019783,0.27233299836039565,9.593406593406593,TGFA_ERBB2,2,2,F1
11,gs_ind_0,Regulation of actin cytoskeleton,1/12,0.45382613699791213,0.5834907475687442,2.52,FN1_ITGB6,2,2,F1
12,gs_ind_0,Signaling by ERBB2,1/1,0.04729729729729731,0.10641891891891894,22.692307692307693,HSP90AA1_ERBB2,2,2,F1
13,gs_ind_0,Signaling by ERBB2 ECD mutants,1/1,0.04729729729729731,0.10641891891891894,22.692307692307693,HSP90AA1_ERBB2,2,2,F1
14,gs_ind_0,Signaling by ERBB2 KD Mutants,1/1,0.04729729729729731,0.10641891891891894,22.692307692307693,HSP90AA1_ERBB2,2,2,F1
15,gs_ind_0,Signaling by ERBB2 in Cancer,1/1,0.04729729729729731,0.10641891891891894,22.692307692307693,HSP90AA1_ERBB2,2,2,F1
16,gs_ind_0,Signaling by NOTCH,1/6,0.2561213867307396,0.4191077237412102,5.059171597633136,ADAM10_NOTCH2,2,2,F1
17,gs_ind_0,Signaling by NOTCH2,1/1,0.04729729729729731,0.10641891891891894,22.692307692307693,ADAM10_NOTCH2,2,2,F1
0,gs_ind_0,Apelin signaling pathway,1/1,0.12162162162162163,0.3648648648648649,8.428571428571429,JAG1_NOTCH3,3,3,F1
1,gs_ind_0,Axon guidance,1/14,0.8514152204335923,0.9996667900124897,0.7950738916256158,EFNB3_EPHB4,3,3,F1
2,gs_ind_0,Bacterial invasion of epithelial cells,1/1,0.12162162162162163,0.3648648648648649,8.428571428571429,FN1_ITGA5,3,3,F1
3,gs_ind_0,Breast cancer,1/18,0.9171463238430156,0.9996667900124897,0.6046332046332046,JAG1_NOTCH3,3,3,F1
4,gs_ind_0,Chemokine signaling pathway,5/21,0.08655704270136487,0.3648648648648649,2.4160206718346253,CCL11_CXCR3;CCL21_CXCR3;CCL19_CXCR3;CXCL12_CXCR3;CCL5_CXCR3,3,3,F1
5,gs_ind_0,Cytokine-cytokine receptor interaction,5/30,0.2858821739274669,0.7718818696041607,1.5828779599271403,TNFSF14_LTBR;IL34_CSF1R;CSF1_CSF1R;LTB_LTBR;IL16_CD4,3,3,F1
6,gs_ind_0,ECM-receptor interaction,1/50,0.9996667900124897,0.9996667900124897,0.16718528995756718,FN1_ITGA5,3,3,F1
7,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/6,0.5472808415652064,0.9996667900124897,1.879120879120879,GAS6_AXL,3,3,F1
8,gs_ind_0,Endocrine resistance,1/16,0.8887823499373876,0.9996667900124897,0.6883116883116883,JAG1_NOTCH3,3,3,F1
9,gs_ind_0,Fibronectin matrix formation,1/1,0.12162162162162163,0.3648648648648649,8.428571428571429,FN1_ITGA5,3,3,F1
10,gs_ind_0,Focal adhesion,3/50,0.9771593132138577,0.9996667900124897,0.4404343660172469,COL1A1_ITGA5;FN1_ITGA5;COL4A2_ITGB5,3,3,F1
11,gs_ind_0,Human papillomavirus infection,4/55,0.9559940683507815,0.9996667900124897,0.5228331780055918,JAG1_NOTCH3;COL1A1_ITGA5;FN1_ITGA5;COL4A2_ITGB5,3,3,F1
12,gs_ind_0,Legionellosis,1/1,0.12162162162162163,0.3648648648648649,8.428571428571429,C3_ITGB2,3,3,F1
13,gs_ind_0,Leishmaniasis,1/1,0.12162162162162163,0.3648648648648649,8.428571428571429,C3_ITGB2,3,3,F1
14,gs_ind_0,MAPK signaling pathway,1/12,0.802403552597476,0.9996667900124897,0.936,CSF1_CSF1R,3,3,F1
15,gs_ind_0,NF-kappa B signaling pathway,2/4,0.07253783817654524,0.3648648648648649,4.865319865319865,LTB_LTBR;TNFSF14_LTBR,3,3,F1
16,gs_ind_0,Notch signaling pathway,1/20,0.9385785985698492,0.9996667900124897,0.5372822299651568,JAG1_NOTCH3,3,3,F1
17,gs_ind_0,Osteoclast differentiation,1/3,0.3242109876160757,0.7957906059667313,3.563265306122449,CSF1_CSF1R,3,3,F1
18,gs_ind_0,PI3K-Akt signaling pathway,4/57,0.9661434974656531,0.9996667900124897,0.49385307346326834,COL4A2_ITGB5;COL1A1_ITGA5;FN1_ITGA5;CSF1_CSF1R,3,3,F1
19,gs_ind_0,Pathways in cancer,1/41,0.998120429161202,0.9996667900124897,0.22203098106712565,JAG1_NOTCH3,3,3,F1
20,gs_ind_0,Proteoglycans in cancer,1/4,0.40810203742925244,0.918229584215818,2.7523809523809524,FN1_ITGA5,3,3,F1
21,gs_ind_0,Rap1 signaling pathway,1/7,0.6046677771414477,0.9996667900124897,1.6171428571428572,CSF1_CSF1R,3,3,F1
22,gs_ind_0,Ras signaling pathway,1/7,0.6046677771414477,0.9996667900124897,1.6171428571428572,CSF1_CSF1R,3,3,F1
23,gs_ind_0,Regulation of actin cytoskeleton,1/12,0.802403552597476,0.9996667900124897,0.936,FN1_ITGA5,3,3,F1
24,gs_ind_0,Tuberculosis,2/3,0.03911249801660761,0.3648648648648649,6.298701298701299,C3_ITGB2;C3_ITGAX,3,3,F1
25,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,3/20,0.4521282136910967,0.939035520743047,1.4154209284028325,TNFSF14_LTBR;CSF1_CSF1R;IL34_CSF1R,3,3,F1
26,gs_ind_0,Yersinia infection,1/1,0.12162162162162163,0.3648648648648649,8.428571428571429,FN1_ITGA5,3,3,F1
0,gs_ind_0,Apoptosis,1/2,0.3527204502814259,0.5878674171357099,3.0864864864864865,TNFSF10_TNFRSF10B,1,1,G2
1,gs_ind_0,Axon guidance,3/20,0.7884524115561665,0.999775461081032,0.8536585365853658,SEMA3C_NRP1;SEMA4C_PLXNB2;SEMA3F_NRP1,1,1,G2
2,gs_ind_0,Bacterial invasion of epithelial cells,1/2,0.3527204502814259,0.5878674171357099,3.0864864864864865,FN1_ITGB1,1,1,G2
3,gs_ind_0,Cytokine-cytokine receptor interaction,1/36,0.999775461081032,0.999775461081032,0.1862273232136246,TNFSF10_TNFRSF10B,1,1,G2
4,gs_ind_0,ECM-receptor interaction,42/119,1.5530828049359555e-08,3.8827070123398885e-07,4.132881258115712,COL6A2_ITGA2;COL4A5_ITGB1;LAMC1_ITGB1;LAMB2_ITGB1;COL6A2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;TNC_SDC4;FN1_ITGB6;LAMA5_ITGB1;COL4A5_ITGA2;COL4A6_ITGAV;SPP1_ITGB5;COL4A6_ITGB1;TNC_SDC1;COL6A1_ITGB1;COL6A1_ITGA2;COL1A1_ITGA2;FN1_ITGB1;LAMA5_ITGA2;COL4A1_ITGA2;COMP_ITGB1;LAMC1_ITGA2;COL4A1_ITGB1;COL4A5_ITGAV;TNC_ITGB6;TNC_ITGAV;COL6A3_ITGB1;LAMB3_ITGB1;THBS2_CD36;COL1A2_ITGB1;THBS2_ITGB1;COL1A1_ITGB1;FN1_ITGAV;COL4A6_ITGA2;COL4A6_ITGA1;SPP1_ITGB1;SPP1_ITGAV;COL6A3_ITGA2;COL1A2_ITGA2;THBS1_ITGB1;THBS1_CD36,1,1,G2
5,gs_ind_0,Fibronectin matrix formation,1/2,0.3527204502814259,0.5878674171357099,3.0864864864864865,FN1_ITGB1,1,1,G2
6,gs_ind_0,Focal adhesion,42/127,2.188816225589337e-07,2.736020281986671e-06,3.689655172413793,COL6A2_ITGA2;COL4A5_ITGB1;LAMC1_ITGB1;FN1_ITGA6;LAMB2_ITGB1;COL6A2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;FN1_ITGB6;LAMA5_ITGB1;COL4A5_ITGA2;COL4A6_ITGAV;SPP1_ITGB5;COL4A6_ITGB1;COL6A1_ITGB1;COL6A1_ITGA2;COL1A1_ITGA2;FN1_ITGB1;LAMA5_ITGA2;COL4A1_ITGA2;COMP_ITGB1;LAMC1_ITGA2;COL4A1_ITGB1;COL4A5_ITGAV;TNC_ITGB6;TNC_ITGAV;COL6A3_ITGB1;LAMB3_ITGB1;VEGFA_EGFR;FN1_ITGA2;COL1A2_ITGB1;THBS2_ITGB1;COL1A1_ITGB1;FN1_ITGAV;COL4A6_ITGA2;TNC_ITGA2;COL4A6_ITGA1;SPP1_ITGB1;SPP1_ITGAV;COL6A3_ITGA2;COL1A2_ITGA2;THBS1_ITGB1,1,1,G2
7,gs_ind_0,Human papillomavirus infection,41/133,5.8001572819980804e-06,4.833464401665067e-05,3.0985864443639,COL6A2_ITGA2;COL4A5_ITGB1;LAMC1_ITGB1;FN1_ITGA6;LAMB2_ITGB1;COL6A2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;FN1_ITGB6;LAMA5_ITGB1;COL4A5_ITGA2;COL4A6_ITGAV;SPP1_ITGB5;COL4A6_ITGB1;COL6A1_ITGB1;COL6A1_ITGA2;COL1A1_ITGA2;FN1_ITGB1;LAMA5_ITGA2;COL4A1_ITGA2;COMP_ITGB1;LAMC1_ITGA2;COL4A1_ITGB1;COL4A5_ITGAV;TNC_ITGB6;TNC_ITGAV;COL6A3_ITGB1;LAMB3_ITGB1;FN1_ITGA2;COL1A2_ITGB1;THBS2_ITGB1;COL1A1_ITGB1;FN1_ITGAV;COL4A6_ITGA2;TNC_ITGA2;COL4A6_ITGA1;SPP1_ITGB1;SPP1_ITGAV;COL6A3_ITGA2;COL1A2_ITGA2;THBS1_ITGB1,1,1,G2
8,gs_ind_0,Influenza A,1/1,0.1951219512195122,0.5420054200542006,5.162162162162162,TNFSF10_TNFRSF10B,1,1,G2
9,gs_ind_0,MAPK signaling pathway,1/32,0.9993905388563997,0.999775461081032,0.21247401247401249,VEGFA_EGFR,1,1,G2
10,gs_ind_0,Natural killer cell mediated cytotoxicity,1/1,0.1951219512195122,0.5420054200542006,5.162162162162162,TNFSF10_TNFRSF10B,1,1,G2
11,gs_ind_0,Necroptosis,1/2,0.3527204502814259,0.5878674171357099,3.0864864864864865,TNFSF10_TNFRSF10B,1,1,G2
12,gs_ind_0,PI3K-Akt signaling pathway,42/147,5.096846346772992e-05,0.000318552896673312,2.7919345412039744,COL6A2_ITGA2;COL4A5_ITGB1;LAMC1_ITGB1;FN1_ITGA6;LAMB2_ITGB1;COL6A2_ITGB1;TNC_ITGB1;LAMB3_ITGA2;FN1_ITGB6;LAMA5_ITGB1;COL4A5_ITGA2;COL4A6_ITGAV;SPP1_ITGB5;COL4A6_ITGB1;COL6A1_ITGB1;COL6A1_ITGA2;COL1A1_ITGA2;FN1_ITGB1;LAMA5_ITGA2;COL4A1_ITGA2;COMP_ITGB1;LAMC1_ITGA2;COL4A1_ITGB1;COL4A5_ITGAV;TNC_ITGB6;TNC_ITGAV;COL6A3_ITGB1;LAMB3_ITGB1;VEGFA_EGFR;FN1_ITGA2;COL1A2_ITGB1;THBS2_ITGB1;COL1A1_ITGB1;FN1_ITGAV;COL4A6_ITGA2;TNC_ITGA2;COL4A6_ITGA1;SPP1_ITGB1;SPP1_ITGAV;COL6A3_ITGA2;COL1A2_ITGA2;THBS1_ITGB1,1,1,G2
13,gs_ind_0,Pathogenic Escherichia coli infection,1/2,0.3527204502814259,0.5878674171357099,3.0864864864864865,TNFSF10_TNFRSF10B,1,1,G2
14,gs_ind_0,Pathways in cancer,19/99,0.5973123830445453,0.8343214044890988,0.9851256281407035,LAMB2_ITGB1;COL4A5_ITGB1;LAMC1_ITGB1;FN1_ITGA6;LAMB3_ITGA2;LAMA5_ITGB1;COL4A5_ITGA2;COL4A6_ITGAV;COL4A6_ITGB1;FN1_ITGB1;LAMA5_ITGA2;COL4A1_ITGA2;LAMC1_ITGA2;COL4A1_ITGB1;COL4A5_ITGAV;LAMB3_ITGB1;FN1_ITGA2;FN1_ITGAV;COL4A6_ITGA2,1,1,G2
15,gs_ind_0,Platelet activation,6/8,0.0008867961826742054,0.004433980913371027,4.232382061735585,COL3A1_ITGB1;COL1A1_ITGA2;COL1A2_ITGA2;COL1A2_ITGB1;COL1A1_ITGB1;COL3A1_ITGA2,1,1,G2
16,gs_ind_0,Proteoglycans in cancer,10/20,0.0014172569658998796,0.005905237357916165,2.9464988198269078,FN1_ITGAV;HSPG2_ITGA2;FN1_SDC2;COL1A2_ITGA2;HSPG2_ITGB1;COL1A1_ITGA2;FN1_ITGB1;FN1_ITGA2;COL1A2_ITGB1;COL1A1_ITGB1,1,1,G2
17,gs_ind_0,Rap1 signaling pathway,1/21,0.9913120574000334,0.999775461081032,0.33500942803268385,VEGFA_EGFR,1,1,G2
18,gs_ind_0,Ras signaling pathway,1/22,0.9931410979473948,0.999775461081032,0.31891891891891894,VEGFA_EGFR,1,1,G2
19,gs_ind_0,Regulation of actin cytoskeleton,5/26,0.6007114112321511,0.8343214044890988,1.0538560175856384,FN1_ITGAV;FN1_ITGA6;FN1_ITGB1;FN1_ITGA2;FN1_ITGB6,1,1,G2
20,gs_ind_0,Small cell lung cancer,19/55,0.002468708657933648,0.008816816635477313,2.1783783783783783,COL4A5_ITGB1;LAMC1_ITGB1;LAMB2_ITGB1;FN1_ITGA6;LAMB3_ITGA2;COL4A5_ITGA2;LAMA5_ITGB1;COL4A6_ITGAV;COL4A6_ITGB1;FN1_ITGB1;LAMA5_ITGA2;COL4A1_ITGA2;COL4A5_ITGAV;COL4A1_ITGB1;LAMC1_ITGA2;LAMB3_ITGB1;FN1_ITGA2;FN1_ITGAV;COL4A6_ITGA2,1,1,G2
21,gs_ind_0,Toxoplasmosis,4/19,0.5275463091011173,0.8242911079704958,1.1802197802197802,LAMB3_ITGB1;LAMB2_ITGB1;LAMC1_ITGB1;LAMA5_ITGB1,1,1,G2
22,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,1/8,0.8280651345832023,0.999775461081032,0.8887122416534181,TNFSF10_TNFRSF10B,1,1,G2
23,gs_ind_0,Wnt signaling pathway,1/10,0.890258020070086,0.999775461081032,0.7142857142857143,SFRP1_FZD6,1,1,G2
24,gs_ind_0,Yersinia infection,1/2,0.3527204502814259,0.5878674171357099,3.0864864864864865,FN1_ITGB1,1,1,G2
0,gs_ind_0,AGE-RAGE signaling pathway in diabetic complications,1/3,0.23121525457854095,0.500966384920172,5.188449848024316,TGFB1_TGFBR2,2,2,G2
1,gs_ind_0,Bacterial invasion of epithelial cells,1/2,0.16052240442484345,0.3682572807393467,7.2893617021276595,FN1_ITGA5,2,2,G2
2,gs_ind_0,Cellular senescence,1/4,0.29618297954373457,0.53380596308389,4.0212765957446805,TGFB1_TGFBR2,2,2,G2
3,gs_ind_0,Chemokine signaling pathway,2/7,0.10869508469539342,0.3682572807393467,4.155555555555556,CCL19_CCR7;CXCL14_CXCR4,2,2,G2
4,gs_ind_0,Chronic myeloid leukemia,1/4,0.29618297954373457,0.53380596308389,4.0212765957446805,TGFB1_TGFBR2,2,2,G2
5,gs_ind_0,Cytokine-cytokine receptor interaction,3/36,0.6035804698373779,0.8005113479623622,1.1216948072634596,CCL19_CCR7;TGFB1_TGFBR2;CSF1_CSF1R,2,2,G2
6,gs_ind_0,ECM-receptor interaction,14/119,0.06322152334998819,0.36236933797909404,1.9472006375772066,COL1A1_ITGAV;COL6A2_ITGA1;COL1A1_ITGA11;COL1A1_ITGA1;COL1A2_ITGA11;COL4A1_ITGA1;COL6A3_ITGA1;COL6A1_ITGA1;FN1_ITGB7;COL1A2_ITGAV;COL1A2_ITGA1;COL4A1_ITGAV;FN1_ITGA5;FN1_ITGA3,2,2,G2
7,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/10,0.5884929057984658,0.8005113479623622,1.6869300911854104,GAS6_AXL,2,2,G2
8,gs_ind_0,Epstein-Barr virus infection,1/1,0.08362369337979093,0.36236933797909404,12.191489361702128,CALR_HLA-F,2,2,G2
9,gs_ind_0,Fibronectin matrix formation,1/2,0.16052240442484345,0.3682572807393467,7.2893617021276595,FN1_ITGA5,2,2,G2
10,gs_ind_0,Focal adhesion,16/127,0.018204542553400788,0.3425669530777792,2.443598615916955,COL1A1_ITGAV;COL6A2_ITGA1;COL1A1_ITGA11;COL1A1_ITGA1;COL1A2_ITGA11;COL4A1_ITGA1;COL1A1_ITGA5;COL6A3_ITGA1;COL4A2_ITGB5;COL6A1_ITGA1;FN1_ITGB7;COL1A2_ITGAV;COL1A2_ITGA1;COL4A1_ITGAV;FN1_ITGA5;FN1_ITGA3,2,2,G2
11,gs_ind_0,FoxO signaling pathway,1/5,0.3558706420559266,0.53380596308389,3.2785299806576402,TGFB1_TGFBR2,2,2,G2
12,gs_ind_0,Gastric cancer,1/12,0.6568298239691177,0.8005113479623622,1.406808510638298,TGFB1_TGFBR2,2,2,G2
13,gs_ind_0,Hepatitis B,1/4,0.29618297954373457,0.53380596308389,4.0212765957446805,TGFB1_TGFBR2,2,2,G2
14,gs_ind_0,Hepatocellular carcinoma,1/11,0.6241469500614146,0.8005113479623622,1.5346901017576318,TGFB1_TGFBR2,2,2,G2
15,gs_ind_0,Herpes simplex virus 1 infection,1/2,0.16052240442484345,0.3682572807393467,7.2893617021276595,CALR_HLA-F,2,2,G2
16,gs_ind_0,Hippo signaling pathway,1/16,0.7623381421125113,0.8922399222669105,1.0502901353965184,TGFB1_TGFBR2,2,2,G2
17,gs_ind_0,Human T-cell leukemia virus 1 infection,1/5,0.3558706420559266,0.53380596308389,3.2785299806576402,TGFB1_TGFBR2,2,2,G2
18,gs_ind_0,Human cytomegalovirus infection,1/5,0.3558706420559266,0.53380596308389,3.2785299806576402,CALR_HLA-F,2,2,G2
19,gs_ind_0,Human immunodeficiency virus 1 infection,1/2,0.16052240442484345,0.3682572807393467,7.2893617021276595,CALR_HLA-F,2,2,G2
20,gs_ind_0,Human papillomavirus infection,16/133,0.030411501683360674,0.3425669530777792,2.2465300727032385,COL1A1_ITGAV;COL6A2_ITGA1;COL1A1_ITGA11;COL1A1_ITGA1;COL1A2_ITGA11;COL4A1_ITGA1;COL1A1_ITGA5;COL6A3_ITGA1;COL4A2_ITGB5;COL6A1_ITGA1;FN1_ITGB7;COL1A2_ITGAV;COL1A2_ITGA1;COL4A1_ITGAV;FN1_ITGA5;FN1_ITGA3,2,2,G2
21,gs_ind_0,Legionellosis,1/1,0.08362369337979093,0.36236933797909404,12.191489361702128,C3_ITGB2,2,2,G2
22,gs_ind_0,Leishmaniasis,1/1,0.08362369337979093,0.36236933797909404,12.191489361702128,C3_ITGB2,2,2,G2
23,gs_ind_0,MAPK signaling pathway,2/32,0.7778501886429476,0.8922399222669105,0.8735042735042735,TGFB1_TGFBR2;CSF1_CSF1R,2,2,G2
24,gs_ind_0,Osteoclast differentiation,2/5,0.0574323294949661,0.36236933797909404,5.707070707070707,TGFB1_TGFBR2;CSF1_CSF1R,2,2,G2
25,gs_ind_0,PI3K-Akt signaling pathway,17/147,0.035135072110541454,0.3425669530777792,2.222598870056497,COL1A1_ITGAV;COL6A2_ITGA1;COL1A1_ITGA11;COL1A1_ITGA1;COL1A2_ITGA11;COL4A1_ITGA1;COL1A1_ITGA5;COL6A3_ITGA1;COL4A2_ITGB5;COL6A1_ITGA1;FN1_ITGB7;COL1A2_ITGAV;CSF1_CSF1R;COL1A2_ITGA1;COL4A1_ITGAV;FN1_ITGA5;FN1_ITGA3,2,2,G2
26,gs_ind_0,Pancreatic cancer,1/5,0.3558706420559266,0.53380596308389,3.2785299806576402,TGFB1_TGFBR2,2,2,G2
27,gs_ind_0,Pathways in cancer,3/99,0.9974418437378315,0.9974418437378315,0.30840247750379807,COL4A1_ITGAV;TGFB1_TGFBR2;FN1_ITGA3,2,2,G2
28,gs_ind_0,Proteoglycans in cancer,1/20,0.836345734291075,0.9112242125120413,0.8329008822003113,FN1_ITGA5,2,2,G2
29,gs_ind_0,Rap1 signaling pathway,1/21,0.8510562300851356,0.9112242125120413,0.7911924789708066,CSF1_CSF1R,2,2,G2
30,gs_ind_0,Ras signaling pathway,1/22,0.864494765716552,0.9112242125120413,0.7531914893617021,CSF1_CSF1R,2,2,G2
31,gs_ind_0,Regulation of actin cytoskeleton,3/26,0.3733724159538904,0.5393157119333973,1.6064063185607722,FN1_ITGA5;FN1_ITGA3;FN1_ITGB7,2,2,G2
32,gs_ind_0,Relaxin signaling pathway,1/5,0.3558706420559266,0.53380596308389,3.2785299806576402,TGFB1_TGFBR2,2,2,G2
33,gs_ind_0,Small cell lung cancer,2/55,0.9652223469508785,0.9906229350285332,0.46546546546546547,COL4A1_ITGAV;FN1_ITGA3,2,2,G2
34,gs_ind_0,TGF-beta signaling pathway,1/12,0.6568298239691177,0.8005113479623622,1.406808510638298,TGFB1_TGFBR2,2,2,G2
35,gs_ind_0,Th17 cell differentiation,1/2,0.16052240442484345,0.3682572807393467,7.2893617021276595,TGFB1_TGFBR2,2,2,G2
36,gs_ind_0,Tuberculosis,2/3,0.019136704117448666,0.3425669530777792,9.031746031746032,C3_ITGB2;C3_ITGAX,2,2,G2
37,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,2/8,0.13763627959234295,0.3682572807393467,3.65359477124183,CCL19_CCR7;CSF1_CSF1R,2,2,G2
38,gs_ind_0,Yersinia infection,1/2,0.16052240442484345,0.3682572807393467,7.2893617021276595,FN1_ITGA5,2,2,G2
0,gs_ind_0,Activated NOTCH1 Transmits Signal to the Nucleus,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,ADAM10_NOTCH1,3,3,G2
1,gs_ind_0,Adrenergic signaling in cardiomyocytes,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,GNAS_ADCY7,3,3,G2
2,gs_ind_0,Aldosterone synthesis and secretion,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,GNAS_ADCY7,3,3,G2
3,gs_ind_0,Axon guidance,4/20,0.42027295040456,0.5796868281442207,1.3498738435660218,SEMA4C_PLXNB2;SEMA4D_PLXNB2;BMP7_BMPR2;NTN1_UNC5C,3,3,G2
4,gs_ind_0,Bile secretion,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,GNAS_ADCY7,3,3,G2
5,gs_ind_0,Breast cancer,2/29,0.9691928755848157,0.9798985784719214,0.48146768485751534,JAG2_NOTCH2;JAG2_NOTCH1,3,3,G2
6,gs_ind_0,Calcium signaling pathway,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,GNAS_ADCY7,3,3,G2
7,gs_ind_0,Circadian entrainment,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,GNAS_ADCY7,3,3,G2
8,gs_ind_0,Constitutive Signaling by NOTCH1 HD Domain Mutants,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,ADAM10_NOTCH1,3,3,G2
9,gs_ind_0,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,ADAM10_NOTCH1,3,3,G2
10,gs_ind_0,Constitutive Signaling by NOTCH1 PEST Domain Mutants,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,ADAM10_NOTCH1,3,3,G2
11,gs_ind_0,Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,ADAM10_NOTCH1,3,3,G2
12,gs_ind_0,Constitutive Signaling by Overexpressed ERBB2,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,HSP90AA1_ERBB2,3,3,G2
13,gs_ind_0,Cortisol synthesis and secretion,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,GNAS_ADCY7,3,3,G2
14,gs_ind_0,Cushing syndrome,1/7,0.7181765191074261,0.8326684279506389,1.206451612903226,GNAS_ADCY7,3,3,G2
15,gs_ind_0,Cytokine-cytokine receptor interaction,4/36,0.8794947694944373,0.9490307113484082,0.7128011336797355,GDF9_BMPR2;BMP7_BMPR2;BMP7_ACVR1;CLCF1_IL6ST,3,3,G2
16,gs_ind_0,Dilated cardiomyopathy (DCM),1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,GNAS_ADCY7,3,3,G2
17,gs_ind_0,ECM-receptor interaction,24/119,0.09748856412813416,0.45462131058081356,1.4700436214724473,LAMA5_ITGB4;COL9A3_ITGB1;COL4A5_ITGB1;COL4A1_ITGB8;LAMA5_ITGA6;TNC_ITGB1;TNC_SDC4;LAMA5_ITGB1;LAMB3_ITGA6;LAMA1_ITGB4;TNC_SDC1;FN1_ITGB8;TNC_ITGB6;LAMC2_ITGA6;LAMB3_ITGB1;THBS1_SDC4;LAMB2_ITGB4;CHAD_ITGA2;CHAD_ITGB1;LAMB3_ITGB4;LAMB3_ITGA3;LAMA5_ITGA3;LAMC2_ITGB4;THBS1_CD36,3,3,G2
18,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,2/10,0.5082639276471256,0.6840084406484088,1.4521193092621665,TGFA_ERBB2;TGFA_ERBB3,3,3,G2
19,gs_ind_0,Endocrine resistance,3/19,0.6304848131596545,0.7759813085041902,1.082973206568712,JAG2_NOTCH2;GNAS_ADCY7;JAG2_NOTCH1,3,3,G2
20,gs_ind_0,Epstein-Barr virus infection,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,CALR_HLA-F,3,3,G2
21,gs_ind_0,Estrogen signaling pathway,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,GNAS_ADCY7,3,3,G2
22,gs_ind_0,Focal adhesion,23/127,0.2914818985096696,0.45462131058081356,1.2074429771908763,LAMA5_ITGB4;COL9A3_ITGB1;COL4A5_ITGB1;FN1_ITGA6;COL4A1_ITGB8;LAMA5_ITGA6;TNC_ITGB1;LAMA5_ITGB1;LAMB3_ITGA6;LAMA1_ITGB4;FN1_ITGB8;TNC_ITGB6;LAMC2_ITGA6;LAMB3_ITGB1;LAMB2_ITGB4;COL6A1_ITGA6;CHAD_ITGA2;CHAD_ITGB1;LAMB3_ITGB4;LAMB3_ITGA3;THBS1_ITGA6;LAMA5_ITGA3;LAMC2_ITGB4,3,3,G2
23,gs_ind_0,Gap junction,1/6,0.6615709481589174,0.8019041795865666,1.3970223325062034,GNAS_ADCY7,3,3,G2
24,gs_ind_0,Gastric acid secretion,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,GNAS_ADCY7,3,3,G2
25,gs_ind_0,Glutamatergic synapse,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,GNAS_ADCY7,3,3,G2
26,gs_ind_0,GnRH signaling pathway,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,GNAS_ADCY7,3,3,G2
27,gs_ind_0,"Growth hormone synthesis, secretion and action",1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,GNAS_ADCY7,3,3,G2
28,gs_ind_0,Herpes simplex virus 1 infection,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,CALR_HLA-F,3,3,G2
29,gs_ind_0,Hippo signaling pathway,1/16,0.9474905643199438,0.9798985784719214,0.530791788856305,BMP7_BMPR2,3,3,G2
30,gs_ind_0,Human cytomegalovirus infection,2/5,0.1894911012687294,0.45462131058081356,2.822177822177822,GNAS_ADCY7;CALR_HLA-F,3,3,G2
31,gs_ind_0,Human immunodeficiency virus 1 infection,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,CALR_HLA-F,3,3,G2
32,gs_ind_0,Human papillomavirus infection,23/133,0.4081206675929385,0.5796868281442207,1.110066498509516,LAMA5_ITGB4;COL9A3_ITGB1;COL4A5_ITGB1;FN1_ITGA6;COL4A1_ITGB8;LAMA5_ITGA6;TNC_ITGB1;LAMA5_ITGB1;LAMB3_ITGA6;LAMA1_ITGB4;FN1_ITGB8;TNC_ITGB6;LAMC2_ITGA6;LAMB3_ITGB1;LAMB2_ITGB4;COL6A1_ITGA6;CHAD_ITGA2;CHAD_ITGB1;LAMB3_ITGB4;LAMB3_ITGA3;THBS1_ITGA6;LAMA5_ITGA3;LAMC2_ITGB4,3,3,G2
33,gs_ind_0,Inflammatory mediator regulation of TRP channels,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,GNAS_ADCY7,3,3,G2
34,gs_ind_0,Insulin secretion,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,GNAS_ADCY7,3,3,G2
35,gs_ind_0,MAPK signaling pathway,4/32,0.8082953466916063,0.9107553202158944,0.813262599469496,AREG_ERBB3;TGFA_ERBB2;TGFA_ERBB3;EREG_ERBB3,3,3,G2
36,gs_ind_0,Melanogenesis,1/7,0.7181765191074261,0.8326684279506389,1.206451612903226,GNAS_ADCY7,3,3,G2
37,gs_ind_0,Morphine addiction,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,GNAS_ADCY7,3,3,G2
38,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,ADAM10_NOTCH2,3,3,G2
39,gs_ind_0,Non-small cell lung cancer,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,TGFA_ERBB2,3,3,G2
40,gs_ind_0,Notch signaling pathway,2/21,0.8897162918891327,0.9490307113484082,0.6810631229235881,JAG2_NOTCH2;JAG2_NOTCH1,3,3,G2
41,gs_ind_0,Ovarian steroidogenesis,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,GNAS_ADCY7,3,3,G2
42,gs_ind_0,Oxytocin signaling pathway,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,GNAS_ADCY7,3,3,G2
43,gs_ind_0,PI3K-Akt signaling pathway,27/147,0.21956881516051918,0.45462131058081356,1.277800744109136,LAMA5_ITGB4;TGFA_ERBB2;COL4A5_ITGB1;FN1_ITGA6;COL4A1_ITGB8;COL9A3_ITGB1;LAMA5_ITGA6;TNC_ITGB1;EREG_ERBB3;LAMA5_ITGB1;AREG_ERBB3;LAMB3_ITGA6;LAMA1_ITGB4;TGFA_ERBB3;FN1_ITGB8;TNC_ITGB6;LAMC2_ITGA6;LAMB3_ITGB1;LAMB2_ITGB4;COL6A1_ITGA6;CHAD_ITGA2;CHAD_ITGB1;LAMB3_ITGB4;LAMB3_ITGA3;THBS1_ITGA6;LAMA5_ITGA3;LAMC2_ITGB4,3,3,G2
44,gs_ind_0,Pancreatic secretion,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,GNAS_ADCY7,3,3,G2
45,gs_ind_0,"Parathyroid hormone synthesis, secretion and action",1/3,0.41642952682747286,0.5796868281442207,2.622119815668203,GNAS_ADCY7,3,3,G2
46,gs_ind_0,Pathways in cancer,11/99,0.9749449479479354,0.9798985784719214,0.5968885523507951,LAMB3_ITGA6;COL4A5_ITGB1;FN1_ITGA6;LAMA5_ITGA6;LAMC2_ITGA6;LAMB3_ITGA3;LAMB3_ITGB1;LAMA5_ITGB1;JAG2_NOTCH2;LAMA5_ITGA3;JAG2_NOTCH1,3,3,G2
47,gs_ind_0,Phospholipase D signaling pathway,1/5,0.5938851377907012,0.7423564222383764,1.656891495601173,GNAS_ADCY7,3,3,G2
48,gs_ind_0,Platelet activation,1/8,0.765482603400108,0.8748372610286949,1.060721062618596,GNAS_ADCY7,3,3,G2
49,gs_ind_0,Programmed Cell Death,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,TNFSF10_RIPK1,3,3,G2
50,gs_ind_0,Prostate cancer,1/5,0.5938851377907012,0.7423564222383764,1.656891495601173,TGFA_ERBB2,3,3,G2
51,gs_ind_0,RIPK1-mediated regulated necrosis,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,TNFSF10_RIPK1,3,3,G2
52,gs_ind_0,Rap1 signaling pathway,1/21,0.9798985784719214,0.9798985784719214,0.39984996249062266,GNAS_ADCY7,3,3,G2
53,gs_ind_0,Regulated Necrosis,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,TNFSF10_RIPK1,3,3,G2
54,gs_ind_0,Regulation of actin cytoskeleton,2/26,0.9495908754469452,0.9798985784719214,0.5421936554012026,FN1_ITGA6;FN1_ITGB8,3,3,G2
55,gs_ind_0,Regulation of lipolysis in adipocytes,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,GNAS_ADCY7,3,3,G2
56,gs_ind_0,Relaxin signaling pathway,1/5,0.5938851377907012,0.7423564222383764,1.656891495601173,GNAS_ADCY7,3,3,G2
57,gs_ind_0,Salivary secretion,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,GNAS_ADCY7,3,3,G2
58,gs_ind_0,Signaling by ERBB2,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,HSP90AA1_ERBB2,3,3,G2
59,gs_ind_0,Signaling by ERBB2 ECD mutants,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,HSP90AA1_ERBB2,3,3,G2
60,gs_ind_0,Signaling by ERBB2 KD Mutants,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,HSP90AA1_ERBB2,3,3,G2
61,gs_ind_0,Signaling by ERBB2 in Cancer,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,HSP90AA1_ERBB2,3,3,G2
62,gs_ind_0,Signaling by NOTCH,2/7,0.3219375224678667,0.4682727599532607,2.0549450549450547,ADAM10_NOTCH2;ADAM10_NOTCH1,3,3,G2
63,gs_ind_0,Signaling by NOTCH1,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,ADAM10_NOTCH1,3,3,G2
64,gs_ind_0,Signaling by NOTCH1 HD Domain Mutants in Cancer,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,ADAM10_NOTCH1,3,3,G2
65,gs_ind_0,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,ADAM10_NOTCH1,3,3,G2
66,gs_ind_0,Signaling by NOTCH1 PEST Domain Mutants in Cancer,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,ADAM10_NOTCH1,3,3,G2
67,gs_ind_0,Signaling by NOTCH1 in Cancer,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,ADAM10_NOTCH1,3,3,G2
68,gs_ind_0,Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,ADAM10_NOTCH1,3,3,G2
69,gs_ind_0,Signaling by NOTCH2,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,ADAM10_NOTCH2,3,3,G2
70,gs_ind_0,Small cell lung cancer,9/55,0.5704586238301934,0.7423564222383764,1.0336960336960337,LAMB3_ITGA6;COL4A5_ITGB1;FN1_ITGA6;LAMA5_ITGA6;LAMC2_ITGA6;LAMB3_ITGA3;LAMB3_ITGB1;LAMA5_ITGB1;LAMA5_ITGA3,3,3,G2
71,gs_ind_0,TCF dependent signaling in response to WNT,1/4,0.5130063304863066,0.6840084406484088,2.032258064516129,DKK1_LRP5,3,3,G2
72,gs_ind_0,TGF-beta signaling pathway,1/12,0.8883649690257055,0.9490307113484082,0.7109677419354838,BMP7_BMPR2,3,3,G2
73,gs_ind_0,Th1 and Th2 cell differentiation,2/7,0.3219375224678667,0.4682727599532607,2.0549450549450547,JAG2_NOTCH2;JAG2_NOTCH1,3,3,G2
74,gs_ind_0,Thermogenesis,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,GNAS_ADCY7,3,3,G2
75,gs_ind_0,Thyroid hormone synthesis,1/1,0.16376306620209058,0.45462131058081356,6.161290322580645,GNAS_ADCY7,3,3,G2
76,gs_ind_0,Toxoplasmosis,5/19,0.18224972453734267,0.45462131058081356,1.781900452488688,LAMB3_ITGA6;LAMA5_ITGA6;LAMC2_ITGA6;LAMB3_ITGB1;LAMA5_ITGB1,3,3,G2
77,gs_ind_0,Vascular smooth muscle contraction,1/7,0.7181765191074261,0.8326684279506389,1.206451612903226,GNAS_ADCY7,3,3,G2
78,gs_ind_0,Wnt signaling pathway,1/10,0.8379585838608931,0.9310650931787701,0.8525345622119815,DKK1_LRP5,3,3,G2
79,gs_ind_0,cAMP signaling pathway,1/2,0.301186618259789,0.45462131058081356,3.6838709677419357,GNAS_ADCY7,3,3,G2
0,gs_ind_0,Axon guidance,5/12,0.013187457637217482,0.2190318158862997,3.6983783783783784,EFNB2_EPHB4;EFNB1_EPHB4;EFNB2_EPHB3;EFNB3_EPHB3;CXCL12_CXCR4,1,1,H1
1,gs_ind_0,Cell adhesion molecules,1/2,0.25719645047254885,0.7656420298614823,4.413333333333333,JAM3_ITGB2,1,1,H1
2,gs_ind_0,Cell adhesion molecules (CAMs),1/2,0.25719645047254885,0.7656420298614823,4.413333333333333,JAM3_ITGB2,1,1,H1
3,gs_ind_0,Chemokine signaling pathway,3/16,0.38282101493074117,0.7656420298614823,1.5676274944567627,CXCL12_CXCR4;CCL19_CCR10;CCL28_CCR10,1,1,H1
4,gs_ind_0,Cytokine-cytokine receptor interaction,4/29,0.5972819311895494,0.8959228967843241,1.0834419817470664,CXCL12_CXCR4;CCL28_CCR10;CSF1_CSF1R;IL34_CSF1R,1,1,H1
5,gs_ind_0,ECM-receptor interaction,10/61,0.30057831269819607,0.7656420298614823,1.3468834688346885,THBS1_SDC1;LAMA4_ITGA6;LAMB1_ITGA6;LAMC1_ITGB4;COL1A2_CD44;COL1A1_CD44;LAMB2_ITGB4;LAMB1_ITGB4;LAMB3_ITGB4;LAMC2_ITGB4,1,1,H1
6,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/3,0.36073876343698147,0.7656420298614823,3.1333333333333333,GAS6_AXL,1,1,H1
7,gs_ind_0,Focal adhesion,7/60,0.7936188372806632,0.9309414075012378,0.8076634109691961,LAMA4_ITGA6;LAMB1_ITGA6;LAMC1_ITGB4;LAMB2_ITGB4;LAMB1_ITGB4;LAMB3_ITGB4;LAMC2_ITGB4,1,1,H1
8,gs_ind_0,Human cytomegalovirus infection,1/4,0.45039125393057555,0.8314915457179857,2.422222222222222,CXCL12_CXCR4,1,1,H1
9,gs_ind_0,Human papillomavirus infection,7/67,0.8957983813686018,0.9347461370802801,0.6767676767676768,LAMA4_ITGA6;LAMB1_ITGA6;LAMC1_ITGB4;LAMB2_ITGB4;LAMB1_ITGB4;LAMB3_ITGB4;LAMC2_ITGB4,1,1,H1
10,gs_ind_0,Intestinal immune network for IgA production,2/2,0.018252651323858306,0.2190318158862997,7.6976744186046515,CXCL12_CXCR4;CCL28_CCR10,1,1,H1
11,gs_ind_0,Leukocyte transendothelial migration,2/3,0.05011182454368371,0.40089459634946967,5.465116279069767,CXCL12_CXCR4;JAM3_ITGB2,1,1,H1
12,gs_ind_0,MAPK signaling pathway,1/13,0.865370406589341,0.9347461370802801,0.762962962962963,CSF1_CSF1R,1,1,H1
13,gs_ind_0,Osteoclast differentiation,1/3,0.36073876343698147,0.7656420298614823,3.1333333333333333,CSF1_CSF1R,1,1,H1
14,gs_ind_0,PI3K-Akt signaling pathway,8/68,0.8019781935941943,0.9309414075012378,0.7965622792559454,LAMA4_ITGA6;LAMB1_ITGA6;CSF1_CSF1R;LAMC1_ITGB4;LAMB2_ITGB4;LAMB1_ITGB4;LAMB3_ITGB4;LAMC2_ITGB4,1,1,H1
15,gs_ind_0,Pathways in cancer,3/41,0.9575009162933933,0.9575009162933933,0.5204231560387893,CXCL12_CXCR4;LAMA4_ITGA6;LAMB1_ITGA6,1,1,H1
16,gs_ind_0,Proteoglycans in cancer,1/10,0.7827468347424069,0.9309414075012378,1.0,DCN_EGFR,1,1,H1
17,gs_ind_0,Rap1 signaling pathway,1/6,0.594963788589298,0.8959228967843241,1.6564102564102565,CSF1_CSF1R,1,1,H1
18,gs_ind_0,Ras signaling pathway,1/6,0.594963788589298,0.8959228967843241,1.6564102564102565,CSF1_CSF1R,1,1,H1
19,gs_ind_0,Regulation of actin cytoskeleton,1/11,0.814573731563583,0.9309414075012378,0.9072463768115943,CXCL12_CXCR4,1,1,H1
20,gs_ind_0,Signaling by EGFR,1/1,0.1377245508982036,0.7656420298614823,7.4,LRIG1_EGFR,1,1,H1
21,gs_ind_0,Small cell lung cancer,2/18,0.7475193025230398,0.9309414075012378,0.9396605908233815,LAMA4_ITGA6;LAMB1_ITGA6,1,1,H1
22,gs_ind_0,Toxoplasmosis,2/8,0.3034823721633818,0.7656420298614823,2.1819425444596443,LAMA4_ITGA6;LAMB1_ITGA6,1,1,H1
23,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,4/19,0.2530752775529864,0.7656420298614823,1.757396449704142,CXCL12_CXCR4;CCL28_CCR10;CSF1_CSF1R;IL34_CSF1R,1,1,H1
0,gs_ind_0,Antigen processing and presentation,2/2,0.003246519010172426,0.03571170911189669,19.470588235294116,HLA-B_KLRD1;HLA-E_KLRD1,2,2,H1
1,gs_ind_0,Bacterial invasion of epithelial cells,1/2,0.11651396003174375,0.18309336576416874,10.452631578947368,FN1_ITGA5,2,2,H1
2,gs_ind_0,Constitutive Signaling by Overexpressed ERBB2,1/1,0.059880239520958084,0.18309336576416874,17.526315789473685,HSP90AA1_ERBB2,2,2,H1
3,gs_ind_0,ECM-receptor interaction,5/61,0.27775912488367666,0.35945298514358154,1.7317073170731707,TNC_SDC1;FN1_ITGB7;TNC_SDC4;FN1_ITGB6;FN1_ITGA5,2,2,H1
4,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/3,0.17005856851466833,0.24941923382151357,7.421052631578948,TGFA_ERBB2,2,2,H1
5,gs_ind_0,Fibronectin matrix formation,1/2,0.11651396003174375,0.18309336576416874,10.452631578947368,FN1_ITGA5,2,2,H1
6,gs_ind_0,Focal adhesion,3/60,0.7658382723365595,0.8023067614954433,0.8292011019283747,FN1_ITGA5;FN1_ITGB6;FN1_ITGB7,2,2,H1
7,gs_ind_0,Graft-versus-host disease,2/2,0.003246519010172426,0.03571170911189669,19.470588235294116,HLA-B_KLRD1;HLA-E_KLRD1,2,2,H1
8,gs_ind_0,Human papillomavirus infection,3/67,0.8425512875072767,0.8425512875072767,0.6948148148148148,FN1_ITGA5;FN1_ITGB6;FN1_ITGB7,2,2,H1
9,gs_ind_0,MAPK signaling pathway,1/13,0.5657347462496842,0.6550612851312133,1.8070175438596492,TGFA_ERBB2,2,2,H1
10,gs_ind_0,Natural killer cell mediated cytotoxicity,1/2,0.11651396003174375,0.18309336576416874,10.452631578947368,HLA-E_KLRD1,2,2,H1
11,gs_ind_0,Non-small cell lung cancer,1/1,0.059880239520958084,0.18309336576416874,17.526315789473685,TGFA_ERBB2,2,2,H1
12,gs_ind_0,PI3K-Akt signaling pathway,4/68,0.6406695910212279,0.7047365501233507,1.0056148231330713,TGFA_ERBB2;FN1_ITGA5;FN1_ITGB6;FN1_ITGB7,2,2,H1
13,gs_ind_0,Prostate cancer,1/1,0.059880239520958084,0.18309336576416874,17.526315789473685,TGFA_ERBB2,2,2,H1
14,gs_ind_0,Proteoglycans in cancer,1/10,0.47024771538399124,0.5747472076915449,2.3684210526315788,FN1_ITGA5,2,2,H1
15,gs_ind_0,Regulation of actin cytoskeleton,3/11,0.019971952724059206,0.14646098664310087,6.350724637681159,FN1_ITGA5;FN1_ITGB6;FN1_ITGB7,2,2,H1
16,gs_ind_0,Signaling by ERBB2,1/2,0.11651396003174375,0.18309336576416874,10.452631578947368,HSP90AA1_ERBB2,2,2,H1
17,gs_ind_0,Signaling by ERBB2 ECD mutants,1/2,0.11651396003174375,0.18309336576416874,10.452631578947368,HSP90AA1_ERBB2,2,2,H1
18,gs_ind_0,Signaling by ERBB2 KD Mutants,1/2,0.11651396003174375,0.18309336576416874,10.452631578947368,HSP90AA1_ERBB2,2,2,H1
19,gs_ind_0,Signaling by ERBB2 in Cancer,1/2,0.11651396003174375,0.18309336576416874,10.452631578947368,HSP90AA1_ERBB2,2,2,H1
20,gs_ind_0,Tuberculosis,1/4,0.22066475336133493,0.3034140358718355,5.7368421052631575,C3_ITGAX,2,2,H1
21,gs_ind_0,Yersinia infection,1/2,0.11651396003174375,0.18309336576416874,10.452631578947368,FN1_ITGA5,2,2,H1
0,gs_ind_0,Cell cycle,1/1,0.0718562874251497,0.24636441402908466,14.478260869565217,TGFB1_SMAD3,3,3,H1
1,gs_ind_0,Chemokine signaling pathway,2/16,0.32232859257654034,0.5844047607733993,2.186147186147186,CCL19_CCR7;CCL19_CXCR3,3,3,H1
2,gs_ind_0,Cytokine-cytokine receptor interaction,2/29,0.6525987735139165,0.8701316980185553,1.1178369652945923,CCL19_CCR7;CSF1_CSF1R,3,3,H1
3,gs_ind_0,ECM-receptor interaction,3/61,0.8818371183447197,0.9620041291033306,0.637997432605905,LAMB2_ITGA3;THBS1_SDC1;LAMB2_ITGB4,3,3,H1
4,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/3,0.2015727580982613,0.4397951085780247,6.130434782608695,GAS6_AXL,3,3,H1
5,gs_ind_0,Epstein-Barr virus infection,1/1,0.0718562874251497,0.24636441402908466,14.478260869565217,CALR_HLA-F,3,3,H1
6,gs_ind_0,Focal adhesion,3/60,0.8729693068911588,0.9620041291033306,0.6546324488908221,LAMB2_ITGA3;COL1A1_ITGA5;LAMB2_ITGB4,3,3,H1
7,gs_ind_0,Herpes simplex virus 1 infection,1/3,0.2015727580982613,0.4397951085780247,6.130434782608695,CALR_HLA-F,3,3,H1
8,gs_ind_0,Human cytomegalovirus infection,1/4,0.2599942636032666,0.5199885272065332,4.739130434782608,CALR_HLA-F,3,3,H1
9,gs_ind_0,Human immunodeficiency virus 1 infection,1/3,0.2015727580982613,0.4397951085780247,6.130434782608695,CALR_HLA-F,3,3,H1
10,gs_ind_0,Human papillomavirus infection,3/67,0.9255284124716009,0.9657687782312356,0.5485380116959064,LAMB2_ITGA3;COL1A1_ITGA5;LAMB2_ITGB4,3,3,H1
11,gs_ind_0,Inflammatory bowel disease,1/1,0.0718562874251497,0.24636441402908466,14.478260869565217,TGFB1_SMAD3,3,3,H1
12,gs_ind_0,Inflammatory bowel disease (IBD),1/1,0.0718562874251497,0.24636441402908466,14.478260869565217,TGFB1_SMAD3,3,3,H1
13,gs_ind_0,Legionellosis,2/2,0.004761561214919559,0.057138734579034706,15.761904761904763,C3_ITGB2;C3_ITGAM,3,3,H1
14,gs_ind_0,Leishmaniasis,2/2,0.004761561214919559,0.057138734579034706,15.761904761904763,C3_ITGB2;C3_ITGAM,3,3,H1
15,gs_ind_0,MAPK signaling pathway,1/13,0.634885264362792,0.8701316980185553,1.4927536231884058,CSF1_CSF1R,3,3,H1
16,gs_ind_0,Osteoclast differentiation,1/3,0.2015727580982613,0.4397951085780247,6.130434782608695,CSF1_CSF1R,3,3,H1
17,gs_ind_0,PI3K-Akt signaling pathway,4/68,0.7990130251832808,0.9588156302199369,0.7689995706311722,LAMB2_ITGA3;COL1A1_ITGA5;LAMB2_ITGB4;CSF1_CSF1R,3,3,H1
18,gs_ind_0,Pathways in cancer,1/41,0.9702952999963583,0.9702952999963583,0.39759036144578314,LAMB2_ITGA3,3,3,H1
19,gs_ind_0,Rap1 signaling pathway,1/6,0.36525297548337454,0.5844047607733993,3.240802675585284,CSF1_CSF1R,3,3,H1
20,gs_ind_0,Ras signaling pathway,1/6,0.36525297548337454,0.5844047607733993,3.240802675585284,CSF1_CSF1R,3,3,H1
21,gs_ind_0,Small cell lung cancer,1/18,0.7579891737536169,0.9574600089519372,1.054054054054054,LAMB2_ITGA3,3,3,H1
22,gs_ind_0,Tuberculosis,2/4,0.026308241583245504,0.21046593266596403,8.65079365079365,C3_ITGB2;C3_ITGAM,3,3,H1
23,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,2/19,0.407154687383021,0.6107320310745316,1.8131868131868132,CCL19_CCR7;CSF1_CSF1R,3,3,H1
0,gs_ind_0,Activated NOTCH1 Transmits Signal to the Nucleus,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,ADAM10_NOTCH1,4,4,H1
1,gs_ind_0,Antigen processing and presentation,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,HLA-B_KLRD1,4,4,H1
2,gs_ind_0,Axon guidance,4/12,0.1922111627835711,0.5594834427530481,1.8976271186440679,EFNB1_EPHB4;SEMA4C_PLXNB2;SEMA4D_PLXNB2;EFNA1_EPHA4,4,4,H1
3,gs_ind_0,Bacterial invasion of epithelial cells,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,FN1_ITGA5,4,4,H1
4,gs_ind_0,Breast cancer,1/16,0.9755902993376143,0.9914970970158706,0.42377622377622376,JAG2_NOTCH2,4,4,H1
5,gs_ind_0,Chemokine signaling pathway,1/16,0.9755902993376143,0.9914970970158706,0.42377622377622376,CXCL9_CXCR3,4,4,H1
6,gs_ind_0,Constitutive Signaling by NOTCH1 HD Domain Mutants,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,ADAM10_NOTCH1,4,4,H1
7,gs_ind_0,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,ADAM10_NOTCH1,4,4,H1
8,gs_ind_0,Constitutive Signaling by NOTCH1 PEST Domain Mutants,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,ADAM10_NOTCH1,4,4,H1
9,gs_ind_0,Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,ADAM10_NOTCH1,4,4,H1
10,gs_ind_0,Constitutive Signaling by Overexpressed ERBB2,1/1,0.19760479041916168,0.5594834427530481,5.123076923076923,HSP90AA1_ERBB2,4,4,H1
11,gs_ind_0,Cytokine-cytokine receptor interaction,2/29,0.9914970970158706,0.9914970970158706,0.37261232176486414,LTB_LTBR;CXCL9_CXCR3,4,4,H1
12,gs_ind_0,ECM-receptor interaction,15/61,0.16165848086744322,0.5594834427530481,1.4508899143045484,COL1A1_ITGAV;FN1_ITGAV;COL4A5_ITGAV;TNC_ITGB6;TNC_ITGAV;TNC_SDC1;FN1_ITGB8;FN1_ITGB7;COL1A2_ITGAV;COL1A2_CD44;TNC_SDC4;FN1_ITGB6;FN1_CD44;COL4A1_ITGAV;FN1_ITGA5,4,4,H1
13,gs_ind_0,EGFR tyrosine kinase inhibitor resistance,1/3,0.4856936728951735,0.6733450399519049,2.169230769230769,TGFA_ERBB2,4,4,H1
14,gs_ind_0,Endocrine resistance,1/12,0.935719908985938,0.9914970970158706,0.5741538461538461,JAG2_NOTCH2,4,4,H1
15,gs_ind_0,Fibronectin matrix formation,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,FN1_ITGA5,4,4,H1
16,gs_ind_0,Focal adhesion,12/60,0.5527315449538512,0.7422395032237431,1.0330578512396693,COL1A1_ITGAV;FN1_ITGAV;COL4A5_ITGAV;TNC_ITGB6;TNC_ITGAV;TNC_ITGA5;FN1_ITGB8;FN1_ITGB7;COL1A2_ITGAV;FN1_ITGB6;COL4A1_ITGAV;FN1_ITGA5,4,4,H1
17,gs_ind_0,Graft-versus-host disease,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,HLA-B_KLRD1,4,4,H1
18,gs_ind_0,Human papillomavirus infection,12/67,0.7532374428642336,0.9065062069369094,0.8656330749354005,COL1A1_ITGAV;FN1_ITGAV;COL4A5_ITGAV;TNC_ITGB6;TNC_ITGAV;TNC_ITGA5;FN1_ITGB8;FN1_ITGB7;COL1A2_ITGAV;FN1_ITGB6;COL4A1_ITGAV;FN1_ITGA5,4,4,H1
19,gs_ind_0,Leukocyte transendothelial migration,1/3,0.4856936728951735,0.6733450399519049,2.169230769230769,VCAM1_EZR,4,4,H1
20,gs_ind_0,MAPK signaling pathway,2/13,0.7714946442016251,0.9065062069369094,0.908289241622575,AREG_ERBB3;TGFA_ERBB2,4,4,H1
21,gs_ind_0,NF-kappa B signaling pathway,1/4,0.5891821411540715,0.7692100176178156,1.676923076923077,LTB_LTBR,4,4,H1
22,gs_ind_0,NOTCH2 Activation and Transmission of Signal to the Nucleus,1/1,0.19760479041916168,0.5594834427530481,5.123076923076923,ADAM10_NOTCH2,4,4,H1
23,gs_ind_0,Non-small cell lung cancer,1/1,0.19760479041916168,0.5594834427530481,5.123076923076923,TGFA_ERBB2,4,4,H1
24,gs_ind_0,Notch signaling pathway,1/16,0.9755902993376143,0.9914970970158706,0.42377622377622376,JAG2_NOTCH2,4,4,H1
25,gs_ind_0,PI3K-Akt signaling pathway,14/68,0.4871006671992504,0.6733450399519049,1.0801048100318174,COL1A1_ITGAV;FN1_ITGAV;TGFA_ERBB2;COL4A5_ITGAV;TNC_ITGB6;TNC_ITGAV;COL4A1_ITGAV;TNC_ITGA5;FN1_ITGB8;FN1_ITGB7;COL1A2_ITGAV;FN1_ITGB6;AREG_ERBB3;FN1_ITGA5,4,4,H1
26,gs_ind_0,Pathways in cancer,4/41,0.9858818714358626,0.9914970970158706,0.4649785583010006,JAG2_NOTCH2;COL4A1_ITGAV;COL4A5_ITGAV;FN1_ITGAV,4,4,H1
27,gs_ind_0,Phospholipase D signaling pathway,1/1,0.19760479041916168,0.5594834427530481,5.123076923076923,ARF1_PLD2,4,4,H1
28,gs_ind_0,Prostate cancer,1/1,0.19760479041916168,0.5594834427530481,5.123076923076923,TGFA_ERBB2,4,4,H1
29,gs_ind_0,Proteoglycans in cancer,3/10,0.3128337614474498,0.5594834427530481,1.721311475409836,FN1_ITGAV;FN1_ITGA5;FN1_SDC2,4,4,H1
30,gs_ind_0,Regulation of actin cytoskeleton,5/11,0.04232527709887393,0.39785760472941495,2.626239511823036,FN1_ITGAV;FN1_ITGA5;FN1_ITGB7;FN1_ITGB6;FN1_ITGB8,4,4,H1
31,gs_ind_0,Signaling by ERBB2,2/2,0.03809248971935647,0.39785760472941495,5.253968253968254,HSP90AA1_ERBB2;HSP90AA1_EGFR,4,4,H1
32,gs_ind_0,Signaling by ERBB2 ECD mutants,2/2,0.03809248971935647,0.39785760472941495,5.253968253968254,HSP90AA1_ERBB2;HSP90AA1_EGFR,4,4,H1
33,gs_ind_0,Signaling by ERBB2 KD Mutants,2/2,0.03809248971935647,0.39785760472941495,5.253968253968254,HSP90AA1_ERBB2;HSP90AA1_EGFR,4,4,H1
34,gs_ind_0,Signaling by ERBB2 in Cancer,2/2,0.03809248971935647,0.39785760472941495,5.253968253968254,HSP90AA1_ERBB2;HSP90AA1_EGFR,4,4,H1
35,gs_ind_0,Signaling by NOTCH,2/7,0.4182340071563368,0.6340967205273493,1.6984126984126984,ADAM10_NOTCH2;ADAM10_NOTCH1,4,4,H1
36,gs_ind_0,Signaling by NOTCH1,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,ADAM10_NOTCH1,4,4,H1
37,gs_ind_0,Signaling by NOTCH1 HD Domain Mutants in Cancer,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,ADAM10_NOTCH1,4,4,H1
38,gs_ind_0,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,ADAM10_NOTCH1,4,4,H1
39,gs_ind_0,Signaling by NOTCH1 PEST Domain Mutants in Cancer,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,ADAM10_NOTCH1,4,4,H1
40,gs_ind_0,Signaling by NOTCH1 in Cancer,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,ADAM10_NOTCH1,4,4,H1
41,gs_ind_0,Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,ADAM10_NOTCH1,4,4,H1
42,gs_ind_0,Signaling by NOTCH2,1/1,0.19760479041916168,0.5594834427530481,5.123076923076923,ADAM10_NOTCH2,4,4,H1
43,gs_ind_0,Small cell lung cancer,3/18,0.7354635062784473,0.9065062069369094,0.9273371732388126,FN1_ITGAV;COL4A1_ITGAV;COL4A5_ITGAV,4,4,H1
44,gs_ind_0,Th1 and Th2 cell differentiation,1/5,0.6723538549081552,0.8540711129914405,1.3636363636363635,JAG2_NOTCH2,4,4,H1
45,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,1/19,0.9884166591190696,0.9914970970158706,0.3514792899408284,CXCL9_CXCR3,4,4,H1
46,gs_ind_0,Yersinia infection,1/2,0.3571170911189669,0.5594834427530481,3.0553846153846154,FN1_ITGA5,4,4,H1
0,gs_ind_0,Bacterial invasion of epithelial cells,1/2,0.11651396003174375,0.15146814804126685,10.452631578947368,FN1_ITGB1,5,5,H1
1,gs_ind_0,ECM-receptor interaction,8/61,0.005184983933425765,0.016851197783633736,5.88780487804878,LAMB2_ITGB1;COL4A1_ITGB1;COL6A1_ITGB1;COL6A2_ITGB1;FN1_ITGB1;COL1A2_ITGB1;COL1A1_ITGB1;COMP_ITGB1,5,5,H1
2,gs_ind_0,Fibronectin matrix formation,1/2,0.11651396003174375,0.15146814804126685,10.452631578947368,FN1_ITGB1,5,5,H1
3,gs_ind_0,Focal adhesion,8/60,0.004576578320096527,0.016851197783633736,6.041322314049586,LAMB2_ITGB1;COL4A1_ITGB1;COL6A1_ITGB1;COL6A2_ITGB1;FN1_ITGB1;COL1A2_ITGB1;COL1A1_ITGB1;COMP_ITGB1,5,5,H1
4,gs_ind_0,Human papillomavirus infection,8/67,0.010419991795540021,0.025164116818885352,5.062222222222222,LAMB2_ITGB1;COL4A1_ITGB1;COL6A1_ITGB1;COL6A2_ITGB1;FN1_ITGB1;COL1A2_ITGB1;COL1A1_ITGB1;COMP_ITGB1,5,5,H1
5,gs_ind_0,PI3K-Akt signaling pathway,8/68,0.011614207762562471,0.025164116818885352,4.938686131386861,LAMB2_ITGB1;COL4A1_ITGB1;COL6A1_ITGB1;COL6A2_ITGB1;FN1_ITGB1;COL1A2_ITGB1;COL1A1_ITGB1;COMP_ITGB1,5,5,H1
6,gs_ind_0,Pathways in cancer,3/41,0.4628198921326208,0.5013882164770058,1.4224899598393574,LAMB2_ITGB1;COL4A1_ITGB1;FN1_ITGB1,5,5,H1
7,gs_ind_0,Platelet activation,3/3,0.00015740698231139031,0.002046290770048074,21.933333333333334,COL1A2_ITGB1;COL3A1_ITGB1;COL1A1_ITGB1,5,5,H1
8,gs_ind_0,Proteoglycans in cancer,4/10,0.0011771952764184797,0.007651769296720117,10.384615384615385,COL1A2_ITGB1;HSPG2_ITGB1;COL1A1_ITGB1;FN1_ITGB1,5,5,H1
9,gs_ind_0,Regulation of actin cytoskeleton,1/11,0.5039898991174948,0.5039898991174948,2.148741418764302,FN1_ITGB1,5,5,H1
10,gs_ind_0,Small cell lung cancer,3/18,0.07815147638212497,0.1451384561382321,3.7711711711711713,LAMB2_ITGB1;COL4A1_ITGB1;FN1_ITGB1,5,5,H1
11,gs_ind_0,Toxoplasmosis,1/8,0.39649751069638234,0.4685879671866337,2.9628482972136223,LAMB2_ITGB1,5,5,H1
12,gs_ind_0,Yersinia infection,1/2,0.11651396003174375,0.15146814804126685,10.452631578947368,FN1_ITGB1,5,5,H1
0,gs_ind_0,AGE-RAGE signaling pathway in diabetic complications,1/2,0.28793016376884784,0.5347274469992889,3.8941176470588235,TGFB1_TGFBR2,6,6,H1
1,gs_ind_0,Antigen processing and presentation,2/2,0.02344708174013419,0.3048120626217445,6.755102040816326,HLA-B_KLRD1;HLA-E_KLRD1,6,6,H1
2,gs_ind_0,Axon guidance,3/12,0.28062638074197593,0.5347274469992889,1.8527659574468085,EFNA1_EPHA4;SEMA4D_PLXNB2;CXCL12_CXCR4,6,6,H1
3,gs_ind_0,Cell adhesion molecules,1/2,0.28793016376884784,0.5347274469992889,3.8941176470588235,JAM3_ITGB2,6,6,H1
4,gs_ind_0,Cell adhesion molecules (CAMs),1/2,0.28793016376884784,0.5347274469992889,3.8941176470588235,JAM3_ITGB2,6,6,H1
5,gs_ind_0,Cellular senescence,1/2,0.28793016376884784,0.5347274469992889,3.8941176470588235,TGFB1_TGFBR2,6,6,H1
6,gs_ind_0,Chemokine signaling pathway,8/16,0.0006711992438953861,0.02617677051192006,4.218673218673219,CXCL14_CXCR4;CXCL9_CXCR3;CCL21_CXCR3;CXCL12_CXCR4;CCL19_CXCR3;CCL21_CCR7;CCL19_CCR7;CCL5_CXCR3,6,6,H1
7,gs_ind_0,Chronic myeloid leukemia,1/2,0.28793016376884784,0.5347274469992889,3.8941176470588235,TGFB1_TGFBR2,6,6,H1
8,gs_ind_0,Cytokine-cytokine receptor interaction,6/29,0.27974259226648635,0.5347274469992889,1.4886316659776768,CXCL9_CXCR3;CCL19_CCR7;CXCL12_CXCR4;TGFB1_TGFBR2;CCL21_CCR7;IL16_CD4,6,6,H1
9,gs_ind_0,ECM-receptor interaction,8/61,0.8109662728988598,0.8939805403354448,0.7956493078444298,COL1A1_ITGAV;FN1_ITGAV;COL4A5_ITGAV;COL1A2_ITGAV;COL1A2_CD44;COL1A1_CD44;FN1_CD44;COL4A1_ITGAV,6,6,H1
10,gs_ind_0,Epstein-Barr virus infection,1/1,0.15568862275449102,0.5347274469992889,6.529411764705882,CALR_HLA-F,6,6,H1
11,gs_ind_0,Focal adhesion,5/60,0.9873847098547809,0.9964340015189528,0.45454545454545453,COL1A1_ITGAV;FN1_ITGAV;COL4A5_ITGAV;COL1A2_ITGAV;COL4A1_ITGAV,6,6,H1
12,gs_ind_0,FoxO signaling pathway,1/2,0.28793016376884784,0.5347274469992889,3.8941176470588235,TGFB1_TGFBR2,6,6,H1
13,gs_ind_0,Gastric cancer,1/4,0.49523563937228526,0.6438063311839708,2.1372549019607843,TGFB1_TGFBR2,6,6,H1
14,gs_ind_0,Graft-versus-host disease,2/2,0.02344708174013419,0.3048120626217445,6.755102040816326,HLA-B_KLRD1;HLA-E_KLRD1,6,6,H1
15,gs_ind_0,Hepatitis B,1/2,0.28793016376884784,0.5347274469992889,3.8941176470588235,TGFB1_TGFBR2,6,6,H1
16,gs_ind_0,Hepatocellular carcinoma,1/4,0.49523563937228526,0.6438063311839708,2.1372549019607843,TGFB1_TGFBR2,6,6,H1
17,gs_ind_0,Herpes simplex virus 1 infection,1/3,0.40013510765981725,0.5779729332864028,2.764705882352941,CALR_HLA-F,6,6,H1
18,gs_ind_0,Hippo signaling pathway,1/3,0.40013510765981725,0.5779729332864028,2.764705882352941,TGFB1_TGFBR2,6,6,H1
19,gs_ind_0,Human T-cell leukemia virus 1 infection,1/3,0.40013510765981725,0.5779729332864028,2.764705882352941,TGFB1_TGFBR2,6,6,H1
20,gs_ind_0,Human cytomegalovirus infection,2/4,0.1148335125224133,0.5347274469992889,3.707482993197279,CXCL12_CXCR4;CALR_HLA-F,6,6,H1
21,gs_ind_0,Human immunodeficiency virus 1 infection,1/3,0.40013510765981725,0.5779729332864028,2.764705882352941,CALR_HLA-F,6,6,H1
22,gs_ind_0,Human papillomavirus infection,5/67,0.9964340015189528,0.9964340015189528,0.38087855297157625,COL1A1_ITGAV;FN1_ITGAV;COL4A5_ITGAV;COL1A2_ITGAV;COL4A1_ITGAV,6,6,H1
23,gs_ind_0,Intestinal immune network for IgA production,1/2,0.28793016376884784,0.5347274469992889,3.8941176470588235,CXCL12_CXCR4,6,6,H1
24,gs_ind_0,Leukocyte transendothelial migration,2/3,0.06352027598690897,0.5347274469992889,4.795918367346939,CXCL12_CXCR4;JAM3_ITGB2,6,6,H1
25,gs_ind_0,MAPK signaling pathway,2/13,0.633827952229874,0.7490693980898511,1.1678004535147393,TGFB1_TGFBR2;EREG_ERBB3,6,6,H1
26,gs_ind_0,Natural killer cell mediated cytotoxicity,1/2,0.28793016376884784,0.5347274469992889,3.8941176470588235,HLA-E_KLRD1,6,6,H1
27,gs_ind_0,Osteoclast differentiation,1/3,0.40013510765981725,0.5779729332864028,2.764705882352941,TGFB1_TGFBR2,6,6,H1
28,gs_ind_0,PI3K-Akt signaling pathway,6/68,0.9885029364640786,0.9964340015189528,0.4605661385081004,COL1A1_ITGAV;FN1_ITGAV;COL4A5_ITGAV;COL1A2_ITGAV;EREG_ERBB3;COL4A1_ITGAV,6,6,H1
29,gs_ind_0,Pancreatic cancer,1/2,0.28793016376884784,0.5347274469992889,3.8941176470588235,TGFB1_TGFBR2,6,6,H1
30,gs_ind_0,Pathways in cancer,5/41,0.8237524422104582,0.8939805403354448,0.7797702437657608,FN1_ITGAV;COL4A5_ITGAV;CXCL12_CXCR4;TGFB1_TGFBR2;COL4A1_ITGAV,6,6,H1
31,gs_ind_0,Proteoglycans in cancer,1/10,0.8252128064634876,0.8939805403354448,0.8823529411764706,FN1_ITGAV,6,6,H1
32,gs_ind_0,Regulation of actin cytoskeleton,2/11,0.5357563076132122,0.6740159999004929,1.388642413487134,CXCL12_CXCR4;FN1_ITGAV,6,6,H1
33,gs_ind_0,Relaxin signaling pathway,1/1,0.15568862275449102,0.5347274469992889,6.529411764705882,TGFB1_TGFBR2,6,6,H1
34,gs_ind_0,Small cell lung cancer,3/18,0.5570113363859007,0.6788575662203166,1.2035652673950545,FN1_ITGAV;COL4A1_ITGAV;COL4A5_ITGAV,6,6,H1
35,gs_ind_0,TGF-beta signaling pathway,1/2,0.28793016376884784,0.5347274469992889,3.8941176470588235,TGFB1_TGFBR2,6,6,H1
36,gs_ind_0,Th17 cell differentiation,1/1,0.15568862275449102,0.5347274469992889,6.529411764705882,TGFB1_TGFBR2,6,6,H1
37,gs_ind_0,Tuberculosis,1/4,0.49523563937228526,0.6438063311839708,2.1372549019607843,C3_ITGAX,6,6,H1
38,gs_ind_0,Viral protein interaction with cytokine and cytokine receptor,4/19,0.3388153302513344,0.5779729332864028,1.523076923076923,CXCL12_CXCR4;CCL19_CCR7;CCL21_CCR7;CXCL9_CXCR3,6,6,H1
